Anticoagulant and fibrinolytic therapy using p38 MAP kinase inhibitors

ABSTRACT

Disclosed are methods for a treating a disease or condition relating to blood coagulation and fibrinolysis using p38 MAP kinase inhibitors.

APPLICATION DATA

This application is a continuation of U.S. application Ser. No. 10/630,599 filed Jul. 30, 2003 which claims benefit to U.S. provisional application Ser. No. 60/403,422 filed Aug. 14, 2002.

TECHNICAL FIELD OF THE INVENTION

The present invention relates to methods of using p38 kinase inhibitors in the treatment of diseases related to blood coagulation and fibrinolysis.

BACKGROUND OF THE INVENTION

Activation of the coagulation system is an important manifestation of the systemic inflammatory response of the host to infection. Levi M, et. al. 1999 N Engl J. Med.; 341: 586-592. Several in vivo models have been used to dissect the molecular mechanisms that contribute to coagulation activation by bacteria and bacterial products, including intravenous injection of low dose lipopolysaccharide (LPS) into healthy humans. Van der Poll T et. al., 1999 Cohen J, Marshall J, ed. The Immune Response in the Critically Ill. Berlin: Springer-Verlag; 335-357. Tissue factor, a glycoprotein expressed on endothelial cells and monocytes upon stimulation, plays an essential role in coagulation activation induced by LPS or bacteria in vivo, as demonstrated by abolishment of this response by inhibitors of tissue factor. de Jonge E, et. al., 2000 Blood 95: 1124-1129; Creasey A A, et. al. 1993 J Clin Invest.; Carr C, et al. 1994 Circ Shock. 44: 126-137; Levi M, et al. 1994 J Clin Invest. 93: 114-120. Mitogen-activated protein kinases (MAPKs), such as p38 MAPK, participate in intracellular signaling cascades that mediate inflammatory responses to infectious and noninfectious stimuli. Herlaar E, et al. 1999 Mol Med Today 5: 439-447; Ono K, et. al. 2000 Cell Signal 12: 1-13. Recent in vitro studies have implicated one of these kinases, p38 MAPK, in the regulation of issue factor expression on monocytes, endothelial cells, and smooth muscle cells. Chu A J, et al. 2001 J Surg Res. 101: 85-90. Blum S, et al. 2001 J Biol. Chem. 276: 33428-33434; Eto M, et. al. 2002 Circulation 105: 1756-1759; Herkert 0, et. al. 2002 Circulation; 105: 2030-2036.

The p38 kinase inhibitors have been discussed in the literature and have been disclosed in U.S. Pat. Nos. 6,319,921, 6,358,945, 5,716,972, U.S. Pat. No. 5,686,455, U.S. Pat. No. 5,656,644, U.S. Pat. No. 5,593,992, U.S. Pat. No. 5,593,991, U.S. Pat. No. 5,663,334, U.S. Pat. No. 5,670,527, U.S. Pat. Nos. 5,559,137, 5,658,903, U.S. Pat. No. 5,739,143, U.S. Pat. No. 5,756,499, U.S. Pat. No. 6,277,989, U.S. Pat. No. 6,340,685, and U.S. Pat. No. 5,716,955; and PCT applications WO 92/12154, WO 94/19350, WO 95/09853, WO 95/09851, WO 95/09847, WO 95/09852, WO 97/25048, WO 97/25047, WO 97/33883, WO 97/35856, WO 97/35855, WO 97/36587, WO 97/47618, WO 97/16442, WO 97/16441, WO 97/12876, WO 98/25619, WO 98/06715, WO 98/07425, WO 98/28292, WO 98/56377, WO 98/07966, WO 98/56377, WO 98/22109, WO 98/24782, WO 98/24780, WO 98/22457, WO 98/52558, WO 98/52559, WO 98/52941, WO 98/52937, WO 98/52940, WO 98/56788, WO 98/27098, WO 98/47892, WO 98/47899, WO 98/50356, WO 98/32733, WO 99/58523, WO 99/01452, WO 99/01131, WO 99/01130, WO 99/01136, WO 99/17776, WO 99/32121, WO 99/58502, WO 99/58523, WO 99/57101, WO 99/61426, WO 99/59960, WO 99/59959, WO 99/00357, WO 99/03837, WO 99/01441, WO 99/01449, WO 99/03484, WO 99/15164, WO 99/32110, WO 99/32111, WO 99/32463, WO 99/64400, WO 99/43680, WO 99/17204, WO 99/25717, WO 99/50238, WO 99/61437, WO 99/61440, WO 00/26209, WO 00/18738, WO 00/17175, WO 00/20402, WO 00/01688, WO 00/07980, WO 00/07991, WO 00/06563, WO 00/12074, WO 00/12497, WO 00/31072, WO 00/31063, WO 00/23072, WO 00/31065, WO 00/35911, WO 00/39116, WO 00/43384, WO 00/41698, WO 00/69848, WO 00/26209, WO 00/63204, WO 00/07985, WO 00/59904, WO 00/71535, WO 00/10563, WO 00/25791, WO 00/55152, WO 00/55139, WO 00/17204, WO 00/36096, WO 00/55120, WO 00/55153, WO 00/56738, WO 01/21591, WO 01/29041, WO 01/29042, WO 01/62731, WO 01/05744, WO 01/05745, WO 01/05746, WO 01/05749, WO 01/05751, WO 01/27315, WO 01/42189, WO 01/00208, WO 01/42241, WO 01/34605, WO 01/47897, WO 01/64676, WO 01/37837, WO 01/38312, WO 01/38313, WO 01/36403, WO 01/38314, WO 01/47921, WO 01/27089, DE 19842833, and JP 2000 86657.

For the most part, such compounds have been indicated as being useful in treating cytokine mediated diseases such as those related to inflammation. Marin et al discusses the issue of whether p38 MAPK is involved in thrombin-induced endothelial proinflammatory functions including chemokine production. Blood, 1 Aug. 2001, Vol. 98 (3) 667-673. Until the present invention however, knowledge of the role of p38 MAPK in activation of coagulation and fibrinolysis has not been available.

SUMMARY OF THE INVENTION

In view of the work cited above there is a clear need for a method of treating diseases or conditions related to coagulation using small molecule inhibitors such as those which inhibit p38 MAP kinase.

It is therefore an object of the invention to provide a method of anticoagulatant and fibrinolytic therapy using inhibitors of p38 MAP kinase either for prevention or for treatment of these hematological physiologic processes in disease states where their activation may cause harm.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Suprisingly, it has been found that p38 MAPK inhibitors possess inhibitory effects on the procoagulant and profibrinolytic responses during human endotoxemia. The invention therefore provides for a method of anticoagulant and fibrinolytic therapy for a disease or condition relating to blood coagulation or fibrinolysis comprising administering to a patient in need thereof a pharmaceutically effective a amount of a p38 MAP kinase inhibitor. This administration may be of benefit given either prophylactically to patients at risk or therapeutically for patients who have developed complications related to these pathways.

The p38 kinase inhibitors within the scope of the present invention the are compounds chosen from those disclosed in U.S. Pat. Nos. 6,319,921, 6,358,945, 5,716,972, U.S. Pat. No. 5,686,455, U.S. Pat. No. 5,656,644, U.S. Pat. No. 5,593,992, U.S. Pat. No. 5,593,991, U.S. Pat. No. 5,663,334, U.S. Pat. No. 5,670,527, U.S. Pat. No. 5,559,137, 5,658,903, U.S. Pat. No. 5,739,143, U.S. Pat. No. 5,756,499, U.S. Pat. No. 6,277,989, U.S. Pat. No. 6,340,685, and U.S. Pat. No. 5,716,955; and PCT applications WO 92/12154, WO 94/19350, WO 95/09853, WO 95/09851, WO 95/09847, WO 95/09852, WO 97/25048, WO 97/25047, WO 97/33883, WO 97/35856, WO 97/35855, WO 97/36587, WO 97/47618, WO 97/16442, WO 97/16441, WO 97/12876, WO 98/25619, WO 98/06715, WO 98/07425, WO 98/28292, WO 98/56377, WO 98/07966, WO 98/56377, WO 98/22109, WO 98/24782, WO 98/24780, WO 98/22457, WO 98/52558, WO 98/52559, WO 98/52941, WO 98/52937, WO 98/52940, WO 98/56788, WO 98/27098, WO 98/47892, WO 98/47899, WO 98/50356, WO 98/32733, WO 99/58523, WO 99/01452, WO 99/01131, WO 99/01130, WO 99/01136, WO 99/17776, WO 99/32121, WO 99/58502, WO 99/58523, WO 99/57101, WO 99/61426, WO 99/59960, WO 99/59959, WO 99/00357, WO 99/03837, WO 99/01441, WO 99/01449, WO 99/03484, WO 99/15164, WO 99/32110, WO 99/32111, WO 99/32463, WO 99/64400, WO 99/43680, WO 99/17204, WO 99/25717, WO 99/50238, WO 99/61437, WO 99/61440, WO 00/26209, WO 00/18738, WO 00/17175, WO 00/20402, WO 00/01688, WO 00/07980, WO 00/07991, WO 00/06563, WO 00/12074, WO 00/12497, WO 00/31072, WO 00/31063, WO 00/23072, WO 00/31065, WO 00/35911, WO 00/39116, WO 00/43384, WO 00/41698, WO 00/69848, WO 00/26209, WO 00/63204, WO 00/07985, WO 00/59904, WO 00/71535, WO 00/10563, WO 00/25791, WO 00/55152, WO 00/55139, WO 00/17204, WO 00/36096, WO 00/55120, WO 00/55153, WO 00/56738, WO 01/21591, WO 01/29041, WO 01/29042, WO 01/62731, WO 01/05744, WO 01/05745, WO 01/05746, WO 01/05749, WO 01/05751, WO 01/27315, WO 01/42189, WO 01/00208, WO 01/42241, WO 01/34605, WO 01/47897, WO 01/64676, WO 01/37837, WO 01/38312, WO 01/38313, WO 01/36403, WO 01/38314, WO 01/47921, WO 01/27089, DE 19842833, and JP 2000 86657 whose disclosures are all incorporated herein by reference in their entirety.

Of particular interest are those p38 inhibitors disclosed in U.S. Pat. Nos. 6,319,921, 6,358,945, U.S. Pat. No. 6,277,989, U.S. Pat. No. 6,340,685, WO 00/12074, WO 00/12497, WO 00/59904, WO 00/71535, WO 01/64676, WO 99/61426, WO 00/10563, WO 00/25791, WO 01/37837, WO 01/38312, WO 01/38313, WO 01/38314, WO 01/47921, WO 99/61437, WO 99/61440, WO 00/17175, WO 00/17204, WO 00/36096, WO 98/27098, WO 99/00357, WO 99/58502, WO 99/64400, WO 99/01131, WO 00/43384, WO 00/55152, WO 00/55139 and WO 01/36403.

In a preferred embodiment the invention provides a method of anticoagulant and fibrinolytic therapy for a disease or condition relating to blood coagulation or fibrinolysis comprising administering to a patient in need thereof a pharmaceutically effective a amount of a p38 MAP kinase inhibitor chosen from the compounds of formula disclosed in WO 00/43384 and corresponding U.S. Pat. No. 6,319,921:

wherein

-   Ar₁ is a heterocyclic group selected from the group consisting of     pyrrole, pyrrolidine, pyrazole, imidazole, oxazole, thiazole, furan     and thiophene; and wherein Ar₁ may be substituted by one or more R₁,     R₂ or R₃; -   Ar₂ is phenyl, naphthyl, quinoline, isoquinoline,     tetrahydronaphthyl, tetrahydroquinoline, tetrahydroisoquinoline,     benzimidazole, benzofuran, indanyl, indenyl or indole each being     optionally substituted with one to three R₂ groups; -   L, a linking group, is a     -   C₁₋₁₀ saturated or unsaturated branched or unbranched carbon         chain;     -   wherein one or more methylene groups are optionally         independently replaced by O, N or S; and     -   wherein said linking group is optionally substituted with 0-2         oxo groups and one or more C₁₋₄ branched or unbranched alkyl         which may be substituted by one or more halogen atoms; -   Q is selected from the group consisting of:     -   a) phenyl, naphthyl, pyridine, pyrimidine, pyridazine,         imidazole, benzimidazole, furan, thiophene, pyran,         naphthyridine, oxazo[4,5-b]pyridine and imidazo[4,5-b]pyridine,         which are optionally substituted with one to three groups         selected from the group consisting of halogen,         -   C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, mono- or di-(C₁₋₃             alkyl)amino, C₁₋₆ alkyl-S(O)_(m) and phenylamino wherein the             phenyl ring is optionally substituted with one to two groups             consisting of halogen, C₁₋₆ alkyl and C₁₋₆ alkoxy;     -   b) tetrahydropyran, tetrahydrofuran, 1,3-dioxolanone,         1,3-dioxanone, 1,4-dioxane, morpholine, thiomorpholine,         thiomorpholine sulfoxide, thiomorpholine sulfone, piperidine,         piperidinone, tetrahydropyrimidone, cyclohexanone, cyclohexanol,         pentamethylene sulfide, pentamethylene sulfoxide, pentamethylene         sulfone, tetramethylene sulfide, tetramethylene sulfoxide and         tetramethylene sulfone which are optionally substituted with one         to three groups selected from the group consisting of C₁₋₆         alkyl, C₁₋₆ alkoxy, hydroxy, mono- or di-(C₁₋₃ alkyl)amino-C₁₋₃         alkyl, phenylamino-C₁₋₃ alkyl and C₁₋₃ alkoxy-C₁₋₃ alkyl;     -   c) C₁₋₆ alkoxy, secondary or tertiary amine wherein the amino         nitrogen is covalently bonded to groups selected from the group         consisting of C₁₋₃ alkyl, C₁₋₅ alkoxyalkyl and phenyl wherein         the phenyl ring is optionally substituted with one to two         halogen, C₁₋₆ alkoxy, hydroxy or mono- or di-(C₁₋₃ alkyl)amino,         C₁₋₆ alkyl-S(O)_(r), phenyl-S(O)_(t), wherein the phenyl ring is         optionally substituted with one to two groups consisting of         halogen, C₁₋₆ alkoxy, hydroxy or mono- or di-(C₁₋₃ alkyl)amino; -   R₁ is selected from the group consisting of:     -   (a) C₃₋₁₀ branched or unbranched alkyl, which may optionally be         partially or fully halogenated, and optionally substituted with         one to three phenyl, naphthyl or heterocyclic groups selected         from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl,         pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,         isoxazolyl and isothiazolyl; each such phenyl, naphthyl or         heterocycle selected from the group hereinabove described, being         substituted with 0 to 5 groups selected from the group         consisting of halogen, C₁₋₆ branched or unbranched alkyl which         is optionally partially or fully halogenated, C₃₋₈ cycloalkyl,         C₅₋₈ cycloalkenyl, hydroxy, cyano, C₁₋₃ alkyloxy which is         optionally partially or fully halogenated, NH₂C(O) and         di(C₁₋₃)alkylaminocarbonyl;     -   (b) C₃₋₇ cycloalkyl selected from the group consisting of         cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl,         cycloheptanyl, bicyclopentanyl, bicyclohexanyl and         bicycloheptanyl, which may optionally be partially or fully         halogenated and which may optionally be substituted with one to         three C₁₋₃alkyl groups, or an analog of such cycloalkyl group         wherein one to three ring methylene groups are replaced by         groups independently selected from O, S, CHOH, >C═O, >C═S and         NH;     -   (c) C₃₋₁₀ branched alkenyl which may optionally be partially or         fully halogenated, and which is optionally substituted with one         to three C₁₋₅ branched or unbranched alkyl, phenyl, naphthyl or         heterocyclic groups, with each such heterocyclic group being         independently selected from the group consisting of pyridinyl,         pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl,         pyrazolyl, thienyl, furyl, isoxazolyl and isothiazolyl, and each         such phenyl, naphthyl or heterocyclic group being substituted         with 0 to 5 groups selected from halogen, C₁₋₆ branched or         unbranched alkyl which is optionally partially or fully         halogenated, cyclopropyl, cyclobutyl, cyclopentanyl,         cyclohexanyl, cycloheptanyl, bicyclopentanyl, bicyclohexanyl and         bicycloheptanyl, hydroxy, cyano, C₁₋₃ alkyloxy which is         optionally partially or fully halogenated, NH₂C(O), mono- or         di(C₁₋₃)alkylaminocarbonyl;     -   (d) C₅₋₇ cycloalkenyl selected from the group consisting of         cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,         cycloheptadienyl, bicyclohexenyl and bicycloheptenyl, wherein         such cycloalkenyl group may optionally be substituted with one         to three C₁₋₃ alkyl groups;     -   (e) cyano; and,     -   (f) methoxycarbonyl, ethoxycarbonyl and propoxycarbonyl; -   R₂ is selected from the group consisting of:     -   a C₁₋₆ branched or unbranched alkyl which may optionally be         partially or fully halogenated, acetyl, aroyl, C₁₋₄ branched or         unbranched alkoxy, which may optionally be partially or fully         halogenated, halogen, methoxycarbonyl and phenylsulfonyl; -   R₃ is selected from the group consisting of:     -   a) a phenyl, naphthyl or heterocyclic group selected from the         group consisting of pyridinyl, pyrimidinyl, pyrazinyl,         pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,         tetrahydrofuryl, isoxazolyl, isothiazolyl, quinolinyl,         isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl,         benzoxazolyl, benzisoxazolyl, benzpyrazolyl, benzothiofuranyl,         cinnolinyl, pterindinyl, phthalazinyl, naphthypyridinyl,         quinoxalinyl, quinazolinyl, purinyl and indazolyl; wherein such         phenyl, naphthyl or heterocyclic group is optionally substituted         with one to five groups selected from the group consisting of a         C₁₋₆ branched or unbranched alkyl, phenyl, naphthyl, heterocycle         selected from the group hereinabove described, C₁₋₆ branched or         unbranched alkyl which is optionally partially or fully         halogenated, cyclopropyl, cyclobutyl, cyclopentanyl,         cyclohexanyl, cycloheptanyl, bicyclopentanyl, bicyclohexanyl,         bicycloheptanyl, phenyl C₁₋₅ alkyl, naphthyl C₁₋₅ alkyl, halo,         hydroxy, cyano, C₁₋₃ alkyloxy which may optionally be partially         or fully halogenated, phenyloxy, naphthyloxy, heteraryloxy         wherein the heterocyclic moiety is selected from the group         hereinabove described, nitro, amino, mono- or         di-(C₁₋₃)alkylamino, phenylamino, naphthylamino,         heterocyclylamino wherein the heterocyclyl moiety is selected         from the group hereinabove described, NH₂C(O), a mono- or         di-(C₁₋₃)alkyl aminocarbonyl, C₁₋₅ alkyl-C(O)—C₁₋₄ alkyl,         amino-C₁₋₅alkyl, mono- or di-(C₁₋₃)alkylamino-C₁₋₅ alkyl,         amino-S(O)₂, di-(C₁₋₃)alkylamino-S(O)₂, R₄—C₁₋₅ alkyl, R₅—C₁₋₅         alkoxy, R₆—C(O)—C₁₋₅ alkyl and R₇—C₁₋₅ alkyl(R₈)N;     -   b) a fused aryl selected from the group consisting of         benzocyclobutanyl, indanyl, indenyl, dihydronaphthyl,         tetrahydronaphthyl, benzocycloheptanyl and benzocycloheptenyl,         or a fused heterocyclyl selected from the group consisting of         cyclopentenopyridine, cyclohexanopyridine,         cyclopentanopyrimidine, cyclohexanopyrimidine,         cyclopentanopyrazine, cyclohexanopyrazine,         cyclopentanopyridazine, cyclohexanopyridazine,         cyclopentanoquinoline, cyclohexanoquinoline,         cyclopentanoisoquinoline, cyclohexanoisoquinoline,         cyclopentanoindole, cyclohexanoindole,         cyclopentanobenzimidazole, cyclohexanobenzimidazole,         cyclopentanobenzoxazole, cyclohexanobenzoxazole,         cyclopentanoimidazole, cyclohexanoimidazole,         cyclopentanothiophene and cyclohexanothiophene; wherein the         fused aryl or fused heterocyclyl ring is substituted with 0 to 3         groups independently selected from phenyl, naphthyl and         heterocyclyl selected from the group consisting of pyridinyl,         pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl,         pyrazolyl, thienyl, furyl, isoxazolyl, and isothiazolyl, C₁₋₆         branched or unbranched alkyl which is optionally partially or         fully halogenated, halo, cyano, C₁₋₃ alkyloxy which is         optionally partially or fully halogenated, phenyloxy,         naphthyloxy, heterocyclyloxy wherein the heterocyclyl moiety is         selected from the group hereinabove described, nitro, amino,         mono- or di-(C₁₋₃)alkylamino, phenylamino, naphthylamino,         heterocyclylamino wherein the heterocyclyl moiety is selected         from the group hereinabove described, NH₂C(O), a mono- or         di-(C₁₋₃)alkyl aminocarbonyl, C₁₋₄ alkyl-OC(O),         -   C₁₋₅ alkyl-C(O)—C₁₋₄ branched or unbranched alkyl, an             amino-C₁₋₅ alkyl, mono- or di-(C₁₋₃)alkylamino-C₁₋₅ alkyl,             R₉—C₁₋₅ alkyl, R₁₀—C₁₋₅ alkoxy, R₁₁—C(O)—C₁₋₅ alkyl, and             R₁₂—C₁₋₅ alkyl(R₁₃)N;     -   c) cycloalkyl selected from the group consisting of         cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,         bicyclohexanyl and bicycloheptanyl, which the cycloalkyl may         optionally be partially or fully halogenated and which may         optionally be substituted with one to three C₁₋₃ alkyl groups;     -   d) C₅₋₇ cycloalkenyl, selected from the group consisting of         cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,         cycloheptadienyl, bicyclohexenyl and bicycloheptenyl, wherein         such cycloalkenyl group may optionally be substituted with one         to three C₁₋₃ alkyl groups; and     -   e) acetyl, aroyl, alkoxycarbonylalkyl or phenylsulfonyl;     -   f) C₁₋₆ branched or unbranched alkyl which may optionally be         partially or fully halogenated;         or R₁ and R₂ taken together may optionally form a fused phenyl         or pyridinyl ring,         and wherein each R₈, R₁₃ is independently selected from the         group consisting of:     -   hydrogen and C₁₋₄ branched or unbranched alkyl which may         optionally be partially or fully halogenated;     -   each R₄, R₅, R₆, R₇, R₉, R₁₀, R₁ ₁ and R₁₂ is independently         selected from the group consisting of:     -   morpholine, piperidine, piperazine, imidazole and tetrazole;     -   m=0, 1, 2;     -   r=0, 1, 2;     -   t=0, 1, 2;     -   X=O or S and physiologically acceptable acids or salts thereof.

In a preferred embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein Ar₂ is naphthyl, tetrahydronaphthyl, indanyl or indenyl.

In a more preferred subgeneric aspect of the invention the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein AR₂ is naphthyl.

A yet more preferred subgeneric aspect of the invention the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein:

-   Ar₁ is thiophene or pyrazole; -   AR₂ is 1-naphthyl; -   L is C₁₋₆ saturated or unsaturated branched or unbranched carbon     chain wherein one or more methylene groups are optionally     independently replaced by O, N or S; and     wherein said linking group is optionally substituted with 0-2 oxo     groups and one or more C₁₋₄ branched or unbranched alkyl which may     be substituted by one or more halogen atoms; -   R₁ is selected from the group consisting of C₁₋₄alkyl branched or     unbranched, cyclopropyl and cyclohexyl which may optionally be     partially or fully halogenated and which may optionally be     substituted with one to three C₁₋₃alkyl groups; -   R₃ is selected from the group consisting of C₃₋₁₀alkyl branched or     unbranched, cyclopropanyl, cyclopentanyl, phenyl, pyridinyl each     being optionally substituted as described above and     alkoxycarbonylalkyl.

In a yet further preferred subgeneric aspect of the invention the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein Ar₁ is pyrazole.

A still yet further preferred subgeneric aspect of previous the invention the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein L is C₁₋₅ saturated carbon chain wherein one or more methylene groups are optionally independently replaced by O, N or S; and

wherein said linking group is optionally substituted with 0-2 oxo groups and one or more C₁₋₄ branched or unbranched alkyl which may be substituted by one or more halogen atoms.

Particularly preferred embodiments of L are propoxy, ethoxy, methoxy, methyl, propyl, C₃₋₅ acetylene or methylamino each being optionally substituted are described herein.

A more particularly preferred embodiment of L is ethoxy optionally substituted.

The following compounds are representative of the compounds the p38 kinase inhibitors which can be used in the methods described herein:

-   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(cis-2,6-dimethylmorpholin-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(trans-2,6-dimethylmorpholin-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(2-(methoxymethyl)morpholin-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(morpholin-4-yl)-2-oxoethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(morpholin-4-yl)-2-methylethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(morpholin-4-yl)-1-methylethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-thiomorpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(1-oxothiomorpholin-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)-3-methylnaphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-piperidin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(1-acetylpiperidin-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-thiazolidin-3-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(morpholin-4-yl-carbonyloxo)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(tetrahydropyran-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(N-methyl-2-methoxyethylamino)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(1-oxo-tetrahydrothiophen-3-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-morpholin-4-yl-propyl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(morpholin-4-yl-methyl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-thiazolidin-3-yl-propyl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(tetrahydopyran-2-yl-oxy)propyl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-pyridin-4-yl-ethyl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-pyridin-4-yl-ethenyl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(morpholin-4-yl)propyn-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(tetrahydropyran-2-yl-oxy)propyn-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(methoxymethyloxy)propyn-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(morpholin-4-yl)-3-methylpropyn-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(morpholin-4-yl)-3,3-dimethylpropyn-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(tetrahydropyran-2-yl-oxy)butyn-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(furan-2-ylcarbonyloxy)propyn-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(piperdin-1-yl)propyn-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(2-methoxymethylmorpholin-4-yl)propyn-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(pyridin-4-yl-methoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-pyridin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-pyridin-4-yl-propoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-imidazol-1-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-benzimidazol-1-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(3,4-dimethoxyphenyl)-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(pyridin-4-yl-methylamino)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(pyridin-4-yl-carbonylamino)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(morpholin-4-yl-acetamido)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(pyridin-3-yl-methylamino)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(pyridin-3-yl-carbonylamino)naphthalen-1-yl]-urea; -   1-[5-iso-Propyl-2-phenyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-(Tetrahydropyran-3-yl)-2-phenyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-cyclohexyl-2-phenyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-(2,2,2-trifluoroethyl)-2-phenyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-(1-methylcycloprop-1-yl)-2-phenyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-ethoxycarbonyl-2-phenyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-(1-methylcyclohex-1-yl)-2-phenyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-methyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-benzyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(4-chlorophenyl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-butyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(ethoxycarbonylmethyl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(4-methyl-3-carbamylphenyl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(4-methyl-3-(2-ethoxycarbonylvinyl)phenyl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(4-methyl-3-(morpholin-4-yl)methylphenyl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(4-methyl-3-dimethylaminomethylphenyl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(3-(2-morpholin-4-yl-ethyl)phenyl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(3-(tetrahydropyran-4-ylamino)phenyl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(3-dimethylaminomethylphenyl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(4-(tetrahydropyran-4-ylamino)phenyl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(4-(3-benzylureido)phenyl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-chloropyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methoxypyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-pyridin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-(trans-2,6-dimethylmorpholin-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(3-morpholin-4-yl-propyn-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(2-dimethylaminomethylmorpholin-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-iso-propyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-cyclopropyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(thiophen-3-yl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-cyclopentyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-iso-propyl-2H-pyrazol-3-yl]-3-[4-(tetrahyropyran-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-cyclopropyl-2H-pyrazol-3-yl]-3-[4-(1-oxo-tetrahydrothiophen-3-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(thiophen-3-yl)-2H-pyrazol-3-yl]-3-[4-(2-pyridinyl-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-cyclopentyl-2H-pyrazol-3-yl]-3-[4-(pyridin-4-yl-methoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(pyridin-4-yl)propyn-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(2-methylaminopyridin-4-yl)propyn-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(1-oxo-tetrahydothiophen-3-yl)propyn-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(thiazolidin-3-yl)propyn-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(tetrahydropyran-4-yl)propyn-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-methylaminopyrimidin-4-yl-methoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(2-methylaminopyrimidin-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(4-methoxybenzimidazol-1-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(4-methylaminobenzimidazol-1-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(2-imidazo[4,5-b]pyridin-1-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-[1,8]naphthyridin-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(3,4-dihydro-2H-pyrano[2,3-b]pyridin-5-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-pyridin-3-yl-2H-pyrazol-3-yl]-3-[4-(2-methylaminopyrimidin-4-yl-methoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-(2-methylpyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-(2-methylaminopyrimidin-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-(2-methylpyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-(4-methoxybenzimidazol-1-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-(2-methylpyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-(4-methylaminobenzimidazol-1-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-(2-methylpyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-(2-imidazo[4,5-b]pyridin-1-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-(2-methylpyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-[1,     8]naphthyridin-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-(2-methylpyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-(3,4-dihydro-2H-pyrano     [2,3-b]pyridin-5-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-cyclopropyl-2H-pyrazol-3-yl]-3-[4-(2-methylaminopyrimidin-4-yl-methoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-cyclopropyl-2H-pyrazol-3-yl]-3-[4-(2-(2-methylaminopyrimidin-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-cyclopropyl-2H-pyrazol-3-yl]-3-[4-(2-(4-methoxybenzimidazol-1-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-cyclopropyl-2H-pyrazol-3-yl]-3-[4-(2-(4-methylaminobenzimidazol-1-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-methyl-2H-pyrazol-3-yl]-3-[4-(2-(2-imidazo[4,5-b]pyridin-1-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-methyl-2H-pyrazol-3-yl]-3-[4-(2-[1,8]naphthyridin-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-methyl-2H-pyrazol-3-yl]-3-[4-(2-(3,4-dihydro-2H-pyrano[2,3-b]pyridin-5-yl)ethoxy)naphthalen-1-yl]-urea     and their physiologically acceptable acids or salts thereof.

The following compounds are preferred p38 kinase inhibitors which can be used in the methods described herein:

-   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(cis-2,6-dimethylmorpholin-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(trans-2,6-dimethylmorpholin-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(2-(methoxymethyl)morpholin-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(morpholin-4-yl)-2-oxoethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(morpholin-4-yl)-2-methylethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(morpholin-4-yl)-1-methylethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-thiomorpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(1-oxothiomorpholin-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)-3-methylnaphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(morpholin-4-yl-carbonyloxo)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(tetrahydropyran-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(1-oxo-tetrahydrothiophen-3-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-morpholin-4-yl-propyl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(morpholin-4-yl-methyl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-pyridin-4-yl-ethyl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(morpholin-4-yl)propyn-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(tetrahydropyran-2-yl-oxy)propyn-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(tetrahydropyran-2-yl-oxy)butyn-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(piperdin-1-yl)propyn-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(2-methoxymethylmorpholin-4-yl)propyn-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(pyridin-4-yl-methoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-pyridin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-pyridin-4-yl-propoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-imidazol-1-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(3,4-dimethoxyphenyl)-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(pyridin-4-yl-methylamino)naphthalen-1-yl]-urea; -   1-[5-iso-Propyl-2-phenyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-cyclohexyl-2-phenyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-(2,2,2-trifluoroethyl)-2-phenyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-(1-methylcycloprop-1-yl)-2-phenyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-(1-methylcyclohex-1-yl)-2-phenyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-methyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(4-chlorophenyl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-butyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(4-methyl-3-carbamylphenyl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(4-methyl-3-(morpholin-4-yl)methylphenyl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(4-methyl-3-dimethylaminomethylphenyl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(3-dimethylaminomethylphenyl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-chloropyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methoxypyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-pyridin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-(trans-2,6-dimethylmorpholin-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(3-morpholin-4-yl-propyn-1-yl)naphthalen-1-yl]-urea.

Particularly preferred p38 kinase inhibitors within the scope of the present invention are the following compounds:

-   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(1-oxothiomorpholin-4-yl)ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-pyridin-4-yl-ethoxy)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methoxypyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea     or -   1-[5-tert-butyl-2-methyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea.

In another preferred embodiment the invention provides a method of anticoagulant and fibrinolytic therapy for a disease or condition relating to blood coagulation or fibrinolysis comprising administering to a patient in need thereof a pharmaceutically effective a amount of a p38 MAP kinase inhibitor chosen from the compounds of formula disclosed in WO 00/55139 and corresponding U.S. Pat. No. 6,358,945:

wherein:

-   Ar₁ is selected from the group consisting of: pyrrole, pyrrolidine,     pyrazole, imidazole, oxazole, thiazole, furan and thiophene;     -   wherein Ar₁ may be substituted by one or more R₁, R₂ or R₃; -   Ar₂ is:     -   phenyl, naphthyl, quinoline, isoquinoline, tetrahydronaphthyl,         tetrahydroquinoline, tetrahydroisoquinoline, benzimidazole,         benzofuran, indanyl, indenyl or indole each being optionally         substituted with zero to three R₂ groups; -   X is:     -   a) a C₅₋₈ cycloalkyl or cycloalkenyl optionally substituted with         0-2 oxo groups or 0-3 C₁₋₄ branched or unbranched alkyl, C₁₋₄         alkoxy or C₁₋₄ alkylamino chains;     -   b) phenyl, furan, thiophene, pyrrole, imidazolyl, pyridine,         pyrimidine, pyridinone, dihydropyridinone, maleimide,         dihydromaleimide, piperdine, piperazine or pyrazine each being         optionally independently substituted with 0-3 C₁₋₄ branched or         unbranched alkyl, C₁₋₄alkoxy, hydroxy, nitrile, mono- or         di-(C₁₋₃ alkyl)amino, C₁₋₆ alkyl-S(O)_(m), or halogen; -   y is:     -   a bond or a C₁₋₄ saturated or unsaturated branched or unbranched         carbon chain optionally partially or fully halogenated, wherein         one or more methylene groups are optionally replaced by O, NH,         S(O), S(O)₂ or S and wherein Y is optionally independently         substituted with 0-2 oxo groups and one or more C₁₋₄ branched or         unbranched alkyl which may be substituted by one or more halogen         atoms; -   Z is:     -   a) phenyl, pyridine, pyrimidine, pyridazine, imidazole, furan,         thiophene, pyran, which are optionally substituted with one to         three groups consisting of halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy,         hydroxy, mono- or di-(C₁₋₃ alkyl)amino, C₁₋₆ alkyl-S(O)_(m),         COOH and phenylamino wherein the phenyl ring is optionally         substituted with one to two groups consisting of halogen, C₁₋₆         alkyl and C₁₋₆ alkoxy;     -   b) tetrahydropyran, tetrahydrofuran, 1,3-dioxolanone,         1,3-dioxanone, 1,4-dioxane, morpholine, thiomorpholine,         thiomorpholine sulfoxide, piperidine, piperidinone, piperazine,         tetrahydropyrimidone, cyclohexanone, cyclohexanol,         pentamethylene sulfide, pentamethylene sulfoxide, pentamethylene         sulfone, tetramethylene sulfide, tetramethylene sulfoxide or         tetramethylene sulfone which are optionally substituted with one         to three groups consisting of nitrile, C₁₋₆ alkyl, C₁₋₆ alkoxy,         hydroxy, mono- or di-(C₁₋₃ alkyl)amino-C₁₋₃ alkyl,         phenylamino-C₁₋₃ alkyl and C₁₋₃ alkoxy-C₁₋₃ alkyl;     -   c) C₁₋₆ alkoxy, secondary or tertiary amine wherein the amino         nitrogen is covalently bonded to groups selected from the group         consisting of C₁₋₃ alkyl, C₁₋₅ alkoxyalkyl, pyridinyl-C₁₋₃         alkyl, imidazolyl-C₁₋₃ alkyl, tetrahydrofuranyl-C₁₋₃ alkyl,         phenylamino, wherein the phenyl ring is optionally substituted         with one to two halogen, C₁₋₆ alkoxy, hydroxy or mono- or         di-(C₁₋₃ alkyl)amino, C₁₋₆ alkyl-S(O)_(m), and phenyl-S(O)_(m),         wherein the phenyl ring is optionally substituted with one to         two halogen, C₁₋₆ alkoxy, hydroxy or mono- or di-(C₁₋₃         alkyl)amino; -   R₁ is:     -   a) C₃₋₁₀ branched or unbranched alkyl optionally partially or         fully halogenated and optionally substituted with one to three         phenyl, naphthyl or heterocyclic groups selected from the group         consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,         pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl and         isothiazolyl; each such phenyl, naphthyl or heterocycle selected         from the group hereinabove described in this paragraph, and         being substituted with 0 to 5 groups selected from the group         consisting of halogen, C₁₋₆ branched or unbranched alkyl which         is optionally partially or fully halogenated, C₃₋₈ cycloalkyl,         C₅₋₈ cycloalkenyl, hydroxy, nitrile, C₁₋₃ alkyloxy which is         optionally partially or fully halogenated, NH₂C(O) and         di(C₁₋₃)alkylaminocarbonyl;     -   b) C₃₋₇ cycloalkyl selected from the group consisting of         cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl,         cycloheptanyl, bicyclopentanyl, bicyclohexanyl and         bicycloheptanyl each being optionally be partially or fully         halogenated and optionally substituted with one to three C₁₋₃         alkyl groups, or an analog of such cycloalkyl group wherein one         to three ring methylene groups are replaced by groups         independently selected from the group consisting of O, S,         CHOH, >C═O, >C═S and NH;     -   c) C₃₋₁₀ branched alkenyl optionally partially or fully         halogenated and optionally substituted with one to three C₁₋₅         branched or unbranched alkyl, phenyl, naphthyl or heterocyclic         groups, with each such heterocyclic group being independently         selected from the group consisting of pyridinyl, pyrimidinyl,         pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl,         thienyl, furyl, isoxazolyl and isothiazolyl, and each such         phenyl, naphthyl or heterocyclic group being substituted with 0         to 5 groups selected from the group consisting of halogen, C₁₋₆         branched or unbranched alkyl which is optionally partially or         fully halogenated, cyclopropyl, cyclobutyl, cyclopentanyl,         cyclohexanyl, cycloheptanyl, bicyclopentanyl, bicyclohexanyl,         bicycloheptanyl, hydroxy, nitrile, C₁₋₃ alkoxy which is         optionally partially or fully halogenated, NH₂C(O) and mono- or         di(C₁₋₃)alkylaminocarbonyl;     -   d) a C₅₋₇ cycloalkenyl selected from the group consisting of         cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,         cycloheptadienyl, bicyclohexenyl and bicycloheptenyl, wherein         such cycloalkenyl group is optionally substituted with one to         three C₁₋₃ alkyl groups;     -   e) nitrile; or     -   f) C₁₋₆ branched or unbranched alkoxycarbonyl, C₁₋₆ branched or         unbranched alkylaminocarbonyl, C₁₋₆ branched or unbranched         alkylcarbonylamino-C₁₋₃-alkyl; -   R₂ is:     -   a C₁₋₆ branched or unbranched alkyl optionally partially or         fully halogenated, acetyl, aroyl, C₁₋₄ branched or unbranched         alkoxy optionally partially or fully halogenated, halogen,         methoxycarbonyl or phenylsulfonyl; -   R₃ is:     -   a) phenyl, naphthyl or heterocyclic group selected from the         group consisting of pyridinyl, pyrimidinyl, pyrazinyl,         pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,         tetrahydrofuryl, isoxazolyl, isothiazolyl, quinolinyl,         isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl,         benzoxazolyl, benzisoxazolyl, benzpyrazolyl, benzothiofuranyl,         cinnolinyl, pterindinyl, phthalazinyl, naphthypyridinyl,         quinoxalinyl, quinazolinyl, purinyl and indazolyl, wherein such         phenyl, naphthyl or heterocyclic group is optionally substituted         with one to five groups selected from the group consisting of         phenyl, naphthyl, heterocycle selected from the group         hereinabove described in this paragraph, C₁₋₆ branched or         unbranched alkyl which is optionally partially or fully         halogenated, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,         cycloheptyl, bicyclopentyl, bicyclohexyl, bicycloheptyl, phenyl         C₁₋₅ alkyl, naphthyl C₁₋₅ alkyl, halogen, hydroxy, nitrile, C₁₋₃         alkyloxy which may optionally be partially or fully halogenated,         phenyloxy, naphthyloxy, heteraryloxy wherein the heterocyclic         moiety is selected from the group hereinabove described in this         paragraph, nitro, amino, mono- or di-(C₁₋₃) alkylamino,         phenylamino, naphthylamino, heterocyclylamino wherein the         heterocyclyl moiety is selected from the group hereinabove         described in this paragraph, NH₂C(O), a mono- or di-(C₁₋₃)alkyl         aminocarbonyl, C₁₋₅ alkyl-C(O)—C₁₋₄ alkyl, amino-C₁₋₅ alkyl,         mono- or di-(C₁₋₃)alkylamino-C₁₋₅ alkyl, amino-S(O)₂,         di-(C₁₋₃)alkylamino-S(O)₂, R₄—C₁₋₅ alkyl, R₅—C₁₋₅ alkoxy,         R₆—C(O)—C₁₋₅ alkyl and R₇—C₁₋₅ alkyl(R₈)N, carboxy-mono- or         di-(C₁₋₅)-alkyl-amino;     -   b) a fused aryl selected from the group consisting of         benzocyclobutanyl, indanyl, indenyl, dihydronaphthyl,         tetrahydronaphthyl, benzocycloheptanyl and benzocycloheptenyl,         or a fused heterocyclyl selected from the group consisting of         cyclopentenopyridine, cyclohexanopyridine,         cyclopentanopyrimidine, cyclohexanopyrimidine,         cyclopentanopyrazine, cyclohexanopyrazine,         cyclopentanopyridazine, cyclohexanopyridazine,         cyclopentanoquinoline, cyclohexanoquinoline,         cyclopentanoisoquinoline, cyclohexanoisoquinoline,         cyclopentanoindole, cyclohexanoindole,         cyclopentanobenzimidazole, cyclohexanobenzimidazole,         cyclopentanobenzoxazole, cyclohexanobenzoxazole,         cyclopentanoimidazole, cyclohexanoimidazole,         cyclopentanothiophene and cyclohexanothiophene; wherein the         fused aryl or fused heterocyclyl ring is substituted with 0 to 3         groups independently selected from the group consisting of         phenyl, naphthyl and heterocyclyl selected from the group         consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,         pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl, and         isothiazolyl, C₁₋₆ branched or unbranched alkyl which is         optionally partially or fully halogenated, halogen, nitrile,         C₁₋₃ alkoxy which is optionally partially or fully halogenated,         phenyloxy, naphthyloxy, heterocyclyloxy wherein the heterocyclyl         moiety is selected from the group hereinabove described in this         paragraph, nitro, amino, mono- or di-(C₁₋₃)alkylamino,         phenylamino, naphthylamino, heterocyclylamino wherein the         heterocyclyl moiety is selected from the group hereinabove         described in this paragraph, NH₂C(O), a mono- or di-(C₁₋₃)alkyl         aminocarbonyl, C₁₋₄ alkyl-OC(O), C₁₋₅ alkyl-C(O)—C₁₋₄ branched         or unbranched alkyl, an amino-C₁₋₅ alkyl, mono- or         di-(C₁₋₃)alkylamino-C₁₋₅ alkyl, R₉—C₁₋₅ alkyl, R₁₀—C₁₋₅ alkoxy,         R₁₁—C(O)—C₁₋₅ alkyl, and R₁₂—C₁₋₅ alkyl(R₁₃)N;     -   c) cycloalkyl selected from the group consisting of cyclopentyl,         cyclohexyl, cycloheptyl, bicyclopentyl, bicyclohexyl and         bicycloheptyl, wherein the cycloalkyl is optionally partially or         fully halogenated and optionally substituted with one to three         C₁₋₃ alkyl groups;     -   d) C₅₋₇ cycloalkenyl selected from the group consisting of         cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,         cycloheptadienyl, bicyclohexenyl and bicycloheptenyl, wherein         such cycloalkenyl group is optionally substituted with one to         three C₁₋₃ alkyl groups;     -   e) acetyl, aroyl, alkoxycarbonylalkyl or phenylsulfonyl; or     -   f) C₁₋₆ branched or unbranched alkyl optionally partially or         fully halogenated;         or R₁ and R₂ taken together may optionally form a fused phenyl         or pyridinyl ring;         each R₈ and R₁₃ is independently selected from the group         consisting of:     -   hydrogen and C₁₋₄ branched or unbranched alkyl optionally be         partially or fully halogenated;         each R₄, R₅, R₆, R₇, R₉, R₁₀, R₁ ₁ and R₁₂ is independently         selected from the group consisting of morpholine, piperidine,         piperazine, imidazole and tetrazole; -   m is 0, 1 or 2; -   W is O or S and pharmaceutically acceptable derivatives thereof.

In a preferred embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein:

-   AR₂ is naphthyl, tetrahydronaphthyl, indanyl or indenyl and W is O.

In another preferred embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein:

-   Ar₁ is selected from thiophene and pyrazole; -   X is C₅₋₇ cycloalkyl or C₅₋₇cycloalkenyl optionally substituted with     0-2 oxo groups or 0-3 C₁₋₄ branched or unbranched alkyl, C₁₋₄ alkoxy     or C₁₋₄ alkylamino; or -   X is phenyl, pyridine, tetrahydropyridine, pyrimidine, furan or     thiophene each being optionally independently substituted with 0-3     C₁₋₄ branched or unbranched alkyl, C₁₋₄alkoxy, hydroxy, nitrile,     mono- or di-(C₁₋₃ alkyl)amino, C₁₋₆ alkyl-S(O)_(m) or halogen; -   R₁ is C₁₋₄alkyl branched or unbranched, cyclopropyl or cyclohexyl     optionally partially or fully halogenated and optionally substituted     with one to three C₁₋₃ alkyl groups; -   R₃ is C₁₋₄alkyl branched or unbranched, phenyl, pyrimidinyl,     pyrazolyl or pyridinyl each being optionally substituted as     described hereinabove in the broadest generic aspect,     alkoxycarbonylalkyl or cyclopropyl or cyclopentyl optionally     substituted as described hereinabove in the broadest generic aspect.

In yet another preferred embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein:

-   Ar₁ is pyrazole; -   X is cyclopentenyl, cyclohexenyl or cycloheptenyl, optionally     substituted with an oxo group or 0-3 C₁₋₄ branched or unbranched     alkyl, C₁₋₄alkoxy or C₁₋₄alkylamino; or X is phenyl, pyridine, furan     or thiophene each being optionally independently substituted with     0-3 C₁₋₄ branched or unbranched alkyl, C₁₋₄alkoxy, hydroxy, nitrile,     mono- or di-(C₁₋₃ alkyl)amino, C₁₋₆ alkyl-S(O)_(m) or halogen.

In yet still another preferred embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein:

-   Y is —CH2—, —CH2CH2—, —CH2NH—, —CH2CH2NH— or a bond; and -   Z is phenyl, imidazole, furan, piperazine, tetrahydropyran,     morpholine, thiomorpholine, thiomorpholine sulfoxide, piperidine,     pyridine, secondary or tertiary amine wherein the amino nitrogen is     covalently bonded to groups selected from the group consisting of     C₁₋₃ alkyl and C₁₋₅ alkoxyalkyl, phenylamino wherein the phenyl ring     is optionally substituted with one to two halogen, C₁₋₆ alkoxy,     hydroxy or mono- or di-(C₁₋₃ alkyl)amino, C₁₋₆ alkyl-S(O)_(m) and     phenyl-S(O)_(m) wherein the phenyl ring is optionally substituted     with one to two halogen, C₁₋₆ alkoxy, hydroxy or mono- or di-(C₁₋₃     alkyl)amino.

In a further embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein:

-   Ar₁ is 5-tert-butyl-pyrazol-3-yl; wherein the pyrazole ring may be     substituted by R₃; -   R₃ is C₁₋₄alkyl branched or unbranched, phenyl, pyrimidinyl,     pyrazolyl, pyridinyl each being optionally substituted as described     hereinabove in the broadest generic aspect, alkoxycarbonylalkyl or     cyclopropyl or cyclopentyl optionally substituted as described     hereinabove in the broadest generic aspect.

In another preferred embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein

X is pyridinyl.

In another preferred embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein

the pyridinyl is attached to Ar₁ via the 3-pyridinyl position.

The following compounds are representative of the compounds the p38 kinase inhibitors which can be used in the methods described herein:

-   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(morpholin-4-yl)phenyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(morpholin-4-yl-methyl)phenyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(2-(morpholin-4-yl)ethyl)phenyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-dimethylaminophenyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(morpholin-4-yl)phenyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(morpholin-4-yl-methyl)phenyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(5-morpholin-4-ylmethyl-pyridin-2-yl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(5-morpholin-4-ylmethyl-fur-2-yl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-methyl-2H-pyrazol-3-yl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-phenyl-2H-pyrazol-3-yl]-3-[4-(4-piperdin-1-ylmethyl-phenyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-phenyl-2H-pyrazol-3-yl]-3-[4-(4-(4-methylpiperazin-1-yl)methylphenyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3,4-di(morpholin-4-yl-methyl)phenyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-pyridin-4-ylmethyl-pyridin-3-yl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(1-oxo-thiomorpholin-4-ylmethyl)pyridin-3-yl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(1-oxo-thiomorpholin-4-ylmethyl)pyridin-3-yl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-tetrahydropyran-4-ylmethyl-pyridin-3-yl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(1-oxo-tetrahydrothiophen-3-ylmethyl)pyridin-3-yl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(imidazol-1-ylmethyl)pyridin-3-yl)naphthalen-1-yl]urea; -   1-[2-(3-dimethylaminomethylphenyl)-5-(1-methyl-cyclohexyl)-2H-pyrazol-3-yl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-1-yl]urea; -   1-[2-(5-(1-methyl-cyclohexyl)-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-ylmethyl-pyrimidin-5-yl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-methoxy-5-(2-morpholin-4-yl-ethoxy)phenyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(2-morpholin-4-yl-ethoxy)phenyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-3-(dimethylamino)phenyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-3-(methylsulfonyl)phenyl)naphthalen-1-yl]urea; -   5-tert-butyl-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-1-yl]ureido}thiophene-2-carboxylic     acid methyl ester; -   5-tert-butyl-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-1-yl]ureido}thiophene-2-carboxylic     acid methylamide; -   5-tert-butyl-1-methyl-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-1-yl]ureido}-1H-pyrrole-2-carboxylic     acid methyl ester; -   5-tert-butyl-1-methyl-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-1-yl]ureido}-1H-pyrrole-2-carboxylic     acid methylamide; -   2-acetylamino     N-(5-tert-butyl-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-1-yl]ureido}thiophen-2-ylmethyl)acetamide; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-morpholin-4-yl-cyclohex-1-enyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-morpholin-4-yl-cylohept-1-enyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(2-morpholin-4-yl-ethylamino)cyclohex-1-enyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-morpholin-4-yl-cyclohept-1-enyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(pyridin-4-yl-methylamino)cyclohex-1-enyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(dimethylaminoethylamino)cyclohex-1-enyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(pyridin-3-yl-methylamino)cyclohex-1-enyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(phenyl-methylamino)cyclohex-1-enyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(2-phenylethylamino)cyclohex-1-enyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(furan-2-yl-methylamino)cyclohex-1-enyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(2-pyridin-2-yl-ethylamino)cyclohex-1-enyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(2-piperdin-1-yl-ethylamino)cyclohex-1-enyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(2-imidazol-4-yl-ethylamino)cyclohex-1-enyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(pyridin-2-yl-methylamino)cyclohex-1-enyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(2-(4-methoxyphenyl)ethylamino)cyclohex-1-enyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-morpholin-4-ylmethyl-3-oxo-cyclohex-1-enyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(1-oxo-tetrahydrothiophen-3-ylmethyl)-3-oxo-cyclohex-1-enyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(1-oxo-thiomorpholin-4-ylmethyl)-3-oxo-cyclohex-1-enyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-methylpiperazin-1-ylmethyl)-3-oxo-cyclohex-1-enyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-{6-oxo-1-(tetrahydro-pyran-4-ylmethyl)-1,2,3,6-tetrahydro-pyridin-4-yl}naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(2-oxo-1-pyridin-4-ylmethyl-piperdin-4-yl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-oxo-1-pyridin-4-yl-1,2,3,6-tetrahydro-pyridin-4-yl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-oxo-1-pyridin-4-yl-1,2,3,6-tetrahydro-pyridin-4-yl)naphthalen-1-yl]urea; -   5-tert-butyl-3-{3-[4-(6-oxo-1-pyridin-4-yl-1,2,3,6-tetrahydro-pyridin-4-yl)naphthalen-1-yl]ureido}thiophene-2-carboxylic     acid methyl ester; -   5-tert-butyl-1-methyl-3-{3-[4-(6-oxo-1-pyridin-4-yl-1,2,3,6-tetrahydro-pyridin-4-yl)naphthalen-1-yl]ureido}pyrrole-2-carboxylic     acid methyl ester; -   5-tert-butyl-1-methyl-3-{3-[4-(6-oxo-1-pyridin-4-yl-1,2,3,6-tetrahydro-pyridin-4-yl)naphthalen-1-yl]ureido}pyrrole-2-carboxylic     acid methyl amide; -   5-tert-butyl-3-{3-[4-(3-morpholin-4-yl-cyclohex-1-enyl)naphthalen-1-yl]ureido}thiophene-2-carboxylic     acid methyl ester; -   5-tert-butyl-1-methyl-3-{3-[4-(3-morpholin-4-yl-cyclohex-1-enyl)naphthalen-1-yl]ureido}pyrrole-2-carboxylic     acid methyl ester; and -   5-tert-butyl-1-methyl-3-{3-[4-(3-morpholin-4-yl-cyclohex-1-enyl)naphthalen-1-yl]ureido}pyrrole-2-carboxylic     acid methyl amide and     the pharmaceutically acceptable derivatives thereof.

The following compounds are preferred compounds of the p38 kinase inhibitors which can be used in the methods described herein:

-   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(morpholin-4-yl-methyl)phenyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(2-(morpholin-4-yl)ethyl)phenyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(morpholin-4-yl-methyl)phenyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(5-morpholin-4-ylmethyl-pyridin-2-yl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(5-morpholin-4-ylmethyl-fur-2-yl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-methyl-2H-pyrazol-3-yl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-1-yl]urea     and     the pharmaceutically acceptable derivatives thereof.

In another preferred embodiment the invention provides a method of anticoagulant and fibrinolytic therapy for a disease or condition relating to blood coagulation or fibrinolysis comprising administering to a patient in need thereof a pharmaceutically effective a amount of a p38 MAP kinase inhibitor chosen from the compounds of formula disclosed in WO 00/55139 and corresponding U.S. Pat. No. 6,358,945:

wherein:

-   Ar₁ is:     -   pyrrole, pyrrolidine, pyrazole, imidazole, oxazole, thiazole,         furan and thiophene;     -   wherein Ar₁ is optionally substituted by one or more R₁, R₂ or         R₃; -   AR₂ is:     -   phenyl, naphthyl, quinoline, isoquinoline, tetrahydronaphthyl,         tetrahydroquinoline, tetrahydroisoquinoline, benzimidazole,         benzofuran, indanyl, indenyl and indole each being optionally         substituted with zero to three R₂ groups; -   X is:     -   a C₅₋₈ cycloalkyl or cycloalkenyl optionally substituted with         one to two oxo groups or one to three C₁₋₄ alkyl, C₁₋₄ alkoxy or         C₁₋₄ alkylamino chains each being branched or unbranched;     -   phenyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl,         pyridinyl, tetrahydropyridinyl, pyrimidinyl, pyridinonyl,         dihydropyridinonyl, maleimidyl, dihydromaleimidyl, piperdinyl,         benzimidazole, 3H-imidazo[4,5-b]pyridine, piperazinyl,         pyridazinyl or pyrazinyl; each being optionally independently         substituted with one to three C₁₋₄ alkyl, C₁₋₄alkoxy, hydroxy,         nitrile, amino, mono- or di-(C₁₋₃ alkyl)amino, mono- or di-(C₁₋₃         alkylamino)carbonyl, NH₂C(O), C₁₋₆ alkyl-S(O)_(m) or halogen; -   Y is:     -   a bond or a C₁₋₄ saturated or unsaturated branched or unbranched         carbon chain optionally partially or fully halogenated, wherein         one or more C atoms are optionally replaced by O, N, or S(O)_(n)         and wherein Y is optionally independently substituted with one         to two oxo groups, nitrile, phenyl, hydroxy or one or more C₁₋₄         alkyl optionally substituted by one or more halogen atoms; -   Z is:     -   aryl, indanyl, heteroaryl selected from benzimidazolyl,         pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, imidazolyl,         pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl and pyranyl,         heterocycle selected from piperazinyl, tetrahydropyrimidonyl,         cyclohexanonyl, cyclohexanolyl, 2-oxa- or         2-thia-5-aza-bicyclo[2.2. I]heptanyl, pentamethylene sulfidyl,         pentamethylene sulfoxidyl, pentamethylene sulfonyl,         tetramethylene sulfidyl, tetramethylene sulfoxidyl or         tetramethylene sulfonyl, tetrahydropyranyl, tetrahydrofuranyl,         1,3-dioxolanonyl, 1,3-dioxanonyl, 1,4-dioxanyl, morpholino,         thiomorpholino, thiomorpholino sulfoxidyl, thiomorpholino         sulfonyl, piperidinyl, piperidinonyl, pyrrolidinyl and         dioxolanyl,         -   each of the aforementioned Z are optionally substituted with             one to three halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₃             alkoxy-C₁₋₃ alkyl, C₁₋₆ alkoxycarbonyl, aroyl, heteroaroyl,             heterocycleC₁₋₃acyl wherein the heteroaryl and heterocycle             are as defined hereinabove in this paragraph, C₁₋₃acyl, oxo,             hydroxy, pyridinyl-C₁₋₃ alkyl, imidazolyl-C₁₋₃ alkyl,             tetrahydrofuranyl-C₁₋₃ alkyl, nitrile-C₁₋₃ alkyl, nitrile,             carboxy, phenyl wherein the phenyl ring is optionally             substituted with one to two halogen, C₁₋₆ alkoxy, hydroxy or             mono- or di-(C₁₋₃ alkyl)amino, amino-S(O)_(m), C₁₋₆             alkyl-S(O)_(m) or phenyl-S(O)_(m) wherein the phenyl ring is             optionally substituted with one to two halogen, C₁₋₆ alkoxy,             hydroxy, halogen or mono- or di-(C₁₋₃ alkyl)amino;     -   or Z is optionally substituted with one to three amino,         aminocarbonyl or amino-C₁₋₃ alkyl wherein the N atom is         optionally independently mono- or di-substituted by         aminoC₁₋₆alkyl, C₁₋₃alkyl, arylC₀₋₃alkyl, C₁₋₅ alkoxyC₁₋₃ alkyl,         C₁₋₅ alkoxy, aroyl, C₁₋₃acyl, C₁₋₃alkyl-S(O)_(m)— or         arylC₀₋₃alkyl-S(O)_(m)— each of the aforementioned alkyl and         aryl attached to the amino group is optionally substituted with         one to two halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy or mono- or         di-(C₁₋₃ alkyl)amino;     -   or Z is optionally substituted with one to three aryl,         heterocycle or heteroaryl as hereinabove described in this         paragraph each in turn is optionally substituted by halogen,         C₁₋₆ alkyl or C₁₋₆ alkoxy;     -   or Z is hydroxy, hydroxyC₁₋₃alkyl, halogen, nitrile, amino         wherein the N atom is optionally independently mono- or         di-substituted by C₁₋₆alkyl, aminoC₁₋₆alkyl, arylC₀₋₃alkyl, C₁₋₅         alkoxyC₁₋₃ alkyl, C₁₋₅ alkoxy, aroyl, C₁₋₃acyl,         C₁₋₃alkyl-S(O)_(m)—, arylC₀₋₃alkyl-S(O)_(m)—, nitrileC₁₋₄alkyl         or C₁₋₃alkoxyC₁₋₃alkyl, each of the aforementioned alkyl and         aryl attached to the amino group is optionally substituted with         one to two halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy or mono- or         di-(C₁₋₃ alkyl)amino, C₁₋₆ alkoxyheteroarylC₀₋₃ alkyl,         heteroarylC₀₋₃alkyl or heterocycyleC₀₋₃alkyl wherein the         heteroaryl and heterocycle is hereinabove described in this         paragraph,     -   or Z is C₁₋₆alkyl branched or unbranched, C₁₋₆alkoxy,         C₁₋₃acylamino, nitrileC₁₋₄alkyl, C₁₋₆ alkyl-S(O)_(m), and         phenyl-S(O)_(m), wherein the phenyl ring is optionally         substituted with one to two halogen, C₁₋₆ alkoxy, hydroxy or         mono- or di-(C₁₋₃ alkyl)amino; -   R₁ is:     -   a) C₁₋₁₀ branched or unbranched alkyl optionally partially or         fully halogenated, and optionally substituted with one to three         phenyl, naphthyl or heterocyclic groups selected from the group         consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,         pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl and         isothiazolyl; each such phenyl, naphthyl or heterocycle,         selected from the group hereinabove described, being substituted         with 0 to 5 groups selected from the group consisting of         halogen, C₁₋₆ branched or unbranched alkyl which is optionally         partially or fully halogenated, C₃₋₈ cycloalkyl, C₅₋₈         cycloalkenyl, hydroxy, nitrile, C₁₋₃ alkyloxy which is         optionally partially or fully halogenated, NH₂C(O) and         di(C₁₋₃)alkylaminocarbonyl;     -   b) C₃₋₇ cycloalkyl selected from the group consisting of         cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,         bicyclopentyl, bicyclohexyl and bicycloheptyl, each optionally         partially or fully halogenated and optionally substituted with         one to three C₁₋₃ alkyl groups, or an analog of such cycloalkyl         group wherein one to three ring methylene groups are replaced by         groups independently selected from the group consisting of O, S,         CHOH, >C═O, >C═S and NH;     -   c) C₃₋₁₀ branched alkenyl optionally partially or fully         halogenated and optionally substituted with one to three C₁₋₅         branched or unbranched alkyl, phenyl, naphthyl or heterocyclic         groups, with each such heterocyclic group being independently         selected from the group consisting of pyridinyl, pyrimidinyl,         pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl,         thienyl, furyl, isoxazolyl and isothiazolyl, and each such         phenyl, naphthyl or heterocyclic group being substituted with 0         to 5 groups selected from the group consisting of halogen, C₁₋₆         branched or unbranched alkyl which is optionally partially or         fully halogenated, cyclopropyl, cyclobutyl, cyclopentanyl,         cyclohexanyl, cycloheptanyl, bicyclopentanyl, bicyclohexanyl,         bicycloheptanyl, hydroxy, nitrile, C₁₋₃ alkoxy which is         optionally partially or fully halogenated, NH₂C(O) and mono- or         di(C₁₋₃)alkylaminocarbonyl;     -   d) a C₅₋₇ cycloalkenyl selected from the group consisting of         cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,         cycloheptadienyl, bicyclohexenyl and bicycloheptenyl, wherein         such cycloalkenyl group is optionally substituted with one to         three C₁₋₃ alkyl groups;     -   e) nitrile; or     -   f) C₁₋₆ branched or unbranched alkoxycarbonyl, C₁₋₆ branched or         unbranched alkylaminocarbonyl, C₁₋₆ branched or unbranched         alkylcarbonylamino-C₁₋₃-alkyl; -   R₂ is:     -   a C₁₋₆ branched or unbranched alkyl optionally partially or         fully halogenated and optionally substituted with nitrile, or R₂         is acetyl, aroyl, C₁₋₄ branched or unbranched alkoxy optionally         partially or fully halogenated, halogen, methoxycarbonyl or         phenylsulfonyl; -   R₃ is:     -   a) phenyl, naphthyl or heterocyclic group selected from the         group consisting of pyridinyl, pyrimidinyl, pyrazinyl,         pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,         tetrahydrofuryl, isoxazolyl, isothiazolyl, quinolinyl,         isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl,         benzoxazolyl, benzisoxazolyl, benzpyrazolyl, benzothiofuranyl,         cinnolinyl, pterindinyl, phthalazinyl, naphthypyridinyl,         quinoxalinyl, quinazolinyl, purinyl and indazolyl, wherein such         phenyl, naphthyl or heterocyclic group is optionally substituted         with one to five groups selected from the group consisting of a         phenyl, naphthyl, heterocycle selected from the group         hereinabove described in this paragraph, C₁₋₆ branched or         unbranched alkyl which is optionally partially or fully         halogenated, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,         cycloheptyl, bicyclopentyl, bicyclohexyl, bicycloheptyl, phenyl         C₁₋₅ alkyl, naphthyl C₁₋₅ alkyl, halogen, hydroxy, oxo, nitrile,         C₁₋₃ alkoxy optionally partially or fully halogenated, C₁₋₃         alkoxyC₁₋₅alkyl, C₁₋₃thioalkyl, C₁₋₃thioalkylC₁₋₅alkyl,         phenyloxy, naphthyloxy, heteraryloxy wherein the heterocyclic         moiety is selected from the group hereinabove described in this         paragraph, nitro, amino, mono- or di-(C₁₋₃)alkylamino,         phenylamino, naphthylamino, heterocyclylamino wherein the         heterocyclyl moiety is selected from the group hereinabove         described in this paragraph, NH₂C(O), a mono- or di-(C₁₋₃)alkyl         aminocarbonyl, C₁₋₅ alkyl-C(O)—C₁₋₄ alkyl, amino-C₁₋₅ alkyl,         mono- or di-(C₁₋₃)alkylamino-C₁₋₅ alkyl, amino-S(O)₂,         di-(C₁₋₃)alkylamino-S(O)₂, R₄—C₁₋₅ alkyl, R₅—C₁₋₅ alkoxy,         R₆—C(O)—C₁₋₅ alkyl and R₇—C₁₋₅ alkyl(R₈)N, carboxy-mono- or         di-(C₁₋₅)-alkyl-amino;     -   b) a fused aryl selected from the group consisting of         benzocyclobutanyl, indanyl, indenyl, dihydronaphthyl,         tetrahydronaphthyl, benzocycloheptanyl and benzocycloheptenyl,         or a fused heterocyclyl selected from the group consisting of         cyclopentenopyridine, cyclohexanopyridine,         cyclopentanopyrimidine, cyclohexanopyrimidine,         cyclopentanopyrazine, cyclohexanopyrazine,         cyclopentanopyridazine, cyclohexanopyridazine,         cyclopentanoquinoline, cyclohexanoquinoline,         cyclopentanoisoquinoline, cyclohexanoisoquinoline,         cyclopentanoindole, cyclohexanoindole,         cyclopentanobenzimidazole, cyclohexanobenzimidazole,         cyclopentanobenzoxazole, cyclohexanobenzoxazole,         cyclopentanoimidazole, cyclohexanoimidazole,         cyclopentanothiophene and cyclohexanothiophene; wherein the         fused aryl or fused heterocyclyl ring is substituted with 0 to 3         groups independently selected from the group consisting of         phenyl, naphthyl and heterocyclyl selected from the group         consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,         pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl, and         isothiazolyl, C₁₋₆ branched or unbranched alkyl which is         optionally partially or fully halogenated, halogen, nitrile,         C₁₋₃ alkoxy which is optionally partially or fully halogenated,         phenyloxy, naphthyloxy, heterocyclyloxy wherein the heterocyclyl         moiety is selected from the group hereinabove described, nitro,         amino, mono- or di-(C₁₋₃)alkylamino, phenylamino, naphthylamino,         heterocyclylamino wherein the heterocyclyl moiety is selected         from the group hereinabove described, NH₂C(O), a mono- or         di-(C₁₋₃)alkyl aminocarbonyl, C₁₋₄ alkyl-OC(O), C₁₋₅         alkyl-C(O)—C₁₋₄ branched or unbranched alkyl, an amino-C₁₋₅         alkyl, mono- or di-(C₁₋₃)alkylamino-C₁₋₅ alkyl, R₉—C₁₋₅ alkyl,         R₁₀—C₁₋₅ alkoxy, R₁₁ —C(O)—C₁₋₅ alkyl and R₁₂—C₁₋₅ alkyl(R₁₃)N;     -   c) cycloalkyl selected from the group consisting of cyclopropyl,         cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclopentyl,         bicyclohexyl and bicycloheptyl, wherein the cycloalkyl is         optionally partially or fully halogenated and optionally         substituted with one to three C₁₋₃ alkyl groups;     -   d) C₅₋₇ cycloalkenyl selected from the group consisting of         cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,         cycloheptadienyl, bicyclohexenyl and bicycloheptenyl, wherein         such cycloalkenyl group is optionally substituted with one to         three C₁₋₃ alkyl groups;     -   e) acetyl, aroyl, C₁₋₆alkoxycarbonylC₁₋₆alkyl or phenylsulfonyl;         or     -   f) C₁₋₆ branched or unbranched alkyl optionally partially or         fully halogenated;         or R₁ and R₂ taken together optionally form a fused phenyl or         pyridinyl ring;         each R₈ and R₁₃ is independently selected from the group         consisting of: hydrogen and C₁₋₄ branched or unbranched alkyl         optionally partially or fully halogenated;         each R₄, R₅, R₆, R₇, R₉, R₁₀, R₁₁ and R₁₂ is independently         selected from the group consisting of morpholine, piperidine,         piperazine, imidazole and tetrazole; -   m is 0, 1 or 2; -   W is O or S;     wherein X is directly attached to one or two —Y-Z, and     pharmaceutically acceptable derivatives thereof.

In a preferred embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein:

-   AR₂ is naphthyl, tetrahydronaphthyl, indanyl or indenyl and -   W is O.

In another preferred embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein:

-   Ar₁ is thiophene or pyrazole each substituted independently by one     to three R₁, R₂ or R₃; -   X is:     -   a C₅₋₇ cycloalkyl or cycloalkenyl optionally substituted with         one to two oxo groups or one to three C₁₋₄ alkyl, C₁₋₄ alkoxy or         C₁₋₄ alkylamino chains each being branched or unbranched;     -   phenyl, indanyl, furanyl, thienyl, imidazolyl, pyridinyl,         pyrazinyl, tetrahydrapyridinyl, pyrimidinyl, pyridinonyl,         piperdinyl, benzimidazole or piperazinyl; each being optionally         independently substituted with one to three C₁₋₄ alkyl,         C₁₋₄alkoxy, hydroxy, nitrile, amino, mono- or di-(C₁₋₃         alkyl)amino, mono- or di-(C₁₋₃ alkylamino)carbonyl, NH₂C(O),         C₁₋₆ alkyl-S(O)_(m) or halogen; -   Y is:     -   a bond or a C₁₋₄ saturated or unsaturated branched or unbranched         carbon chain optionally partially or fully halogenated, wherein         one or more C atoms are optionally replaced by O or N, and         wherein Y is optionally independently substituted with one to         two oxo groups, nitrile, phenyl, hydroxy or one or more C₁₋₄         alkyl optionally substituted by one or more halogen atoms; -   Z is:     -   phenyl, heteroaryl selected from pyridinyl, imidazolyl, furanyl         and thienyl, heterocycle selected from piperazinyl,         2-oxa-5-aza-bicyclo[2.2.1]heptanyl, pentamethylene sulfidyl,         pentamethylene sulfoxidyl, pentamethylene sulfonyl,         tetrahydrofuranyl, morpholino, thiomorpholino and piperidinyl,     -   each of the aforementioned Z are optionally substituted with one         to three halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₃alkoxy-C₁₋₃         alkyl, C₁₋₆ alkoxycarbonyl, aroyl, morpholinocarbonyl, C₁₋₃acyl,         oxo, hydroxy, pyridinyl-C₁₋₃ alkyl, imidazolyl-C₁₋₃ alkyl,         tetrahydrofuranyl-C₁₋₃ alkyl, nitrile-C₁₋₃ alkyl, nitrile,         carboxy, phenyl wherein the phenyl ring is optionally         substituted with one to two halogen, C₁₋₆ alkoxy, hydroxy or         mono- or di-(C₁₋₃ alkyl)amino, amino-S(O)_(m), C₁₋₆         alkyl-S(O)_(m) or phenyl-S(O)_(m) wherein the phenyl ring is         optionally substituted with one to two halogen, C₁₋₆ alkoxy,         hydroxy, halogen or mono- or di-(C₁₋₃ alkyl)amino;     -   or Z is optionally substituted with one to three amino,         aminocarbonyl or amino-C-₁₋₃ alkyl wherein the N atom is         optionally independently mono- or di-substituted by aminoC₁₋₆         alkyl, C₁₋₃alkyl, arylC₀₋₃alkyl, C₁₋₅ alkoxyC₁₋₁₃ alkyl, C₁₋₅         alkoxy, aroyl, C₁₋₃acyl, C₁₋₃alkyl-S(O)_(n)— or         arylC₀₋₃alkyl-S(O)_(m)— each of the aforementioned alkyl and         aryl attached to the amino group are optionally substituted with         one to two halogen, C₁₋₆ alkyl or C₁₋₆ alkoxy;     -   or Z is optionally substituted with one to three aryl,         heterocycle or heteroaryl as hereinabove described in this         paragraph each in turn is optionally substituted by halogen,         C₁₋₆ alkyl or C₁₋₆ alkoxy;     -   or Z is hydroxy, hydroxyC₁₋₃alkyl, halogen, nitrile, amino         wherein the N atom is optionally independently mono- or         di-substituted by aroyl, C₁₋₃acyl, C₁₋₆alkyl, C₁₋₅ alkoxyc₁₋₃         alkyl, pyridinylC₁₋₃alkyl, tetrahydrafuranylC₁₋₃alkyl,         nitrileC₁₋₄alkyl or phenyl wherein the phenyl ring is optionally         substituted with one to two halogen, C₁₋₆ alkoxy, hydroxy or         mono- or di-(C₁₋₃ alkyl)amino,     -   or Z is C₁₋₆alkyl branched or unbranched, C₁₋₆alkoxy or         nitrileC₁₋₄alkyl; -   R₁ is:     -   C₁₋₄ branched or unbranched alkyl optionally partially or fully         halogenated;     -   cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl         optionally partially or fully halogenated and optionally         substituted with one to three C₁₋₃ alkyl groups, or an analog of         such cycloalkyl group wherein one to three ring methylene groups         are replaced by groups independently selected from the group         consisting of O, S and NH;     -   C₃₋₁₀ branched alkenyl optionally partially or fully halogenated         and optionally substituted with one to three C₁₋₅ branched or         unbranched alkyl;     -   cyclopentenyl and cyclohexenyl optionally substituted with one         to three C₁₋₃ alkyl groups; -   R₂ is:     -   a C₁₋₆ branched or unbranched alkyl optionally partially or         fully halogenated and optionally substituted with nitrile; -   R₃ is:     -   phenyl or heterocyclic group selected from the group consisting         of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl and pyrazolyl,         wherein such phenyl or heterocyclic group is optionally         substituted with one to five groups selected from the group         consisting of a phenyl, heterocycle selected from the group         hereinabove described in this paragraph, C₁₋₆ branched or         unbranched alkyl which is optionally partially or fully         halogenated, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,         cycloheptyl, bicyclopentyl, bicyclohexyl, bicycloheptyl, phenyl         C₁₋₅ alkyl, naphthyl C₁₋₅ alkyl, halogen, hydroxy, oxo, nitrile,         C₁₋₃ alkoxy optionally be partially or fully halogenated, C₁₋₃         alkoxyC₁₋₅alkyl, C₁₋₃thioalkyl, C₁₋₃thioalkylC₁₋₅alkyl,         phenyloxy, naphthyloxy, heteraryloxy wherein the heterocyclic         moiety is selected from the group hereinabove described in this         paragraph, nitro, amino, mono- or di-(C₁₋₃)alkylamino,         phenylamino, naphthylamino, heterocyclylamino wherein the         heterocyclyl moiety is selected from the group hereinabove         described in this paragraph, NH₂C(O), a mono- or di-(C₁₋₃)alkyl         aminocarbonyl, C₁₋₅ alkyl-C(O)—C₁₋₄ alkyl, amino-C₁₋₅ alkyl,         mono- or di-(C₁₋₃)alkylamino-C₁₋₅ alkyl, amino-S(O)₂,         di-(C₁₋₃)alkylamino-S(O)₂, R₄—C₁₋₅ alkyl, R₅—C₁₋₅ alkoxy,         R₆—C(O)—C₁₋₅ alkyl and R₇—C₁₋₅ alkyl(R₈)N, carboxy-mono- or         di-(C₁₋₅)-alkyl-amino;     -   a fused aryl selected from the group consisting of         benzocyclobutanyl, indanyl, indenyl; wherein the fused aryl is         substituted with 0 to 3 groups independently selected from the         group consisting of phenyl, naphthyl and heterocyclyl selected         from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl,         pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,         isoxazolyl, and isothiazolyl, C₁₋₆ branched or unbranched alkyl         which is optionally partially or fully halogenated, halogen,         nitrile, C₁₋₃ alkoxy which is optionally partially or fully         halogenated, phenyloxy, naphthyloxy, heterocyclyloxy wherein the         heterocyclyl moiety is selected from the group hereinabove         described in this paragraph, nitro, amino, mono- or         di-(C₁₋₃)alkylamino, phenylamino, naphthylamino,         heterocyclylamino wherein the heterocyclyl moiety is selected         from the group hereinabove described in this paragraph, NH₂C(O),         a mono- or di-(C₁₋₃)alkyl aminocarbonyl, C₁₋₄ alkyl-OC(O), C₁₋₅         alkyl-C(O)—C₁₋₄ branched or unbranched alkyl, an amino-C₁₋₅         alkyl, mono- or di-(C₁₋₃)alkylamino-C 5 alkyl, R₉—C₁₋₅ alkyl,         R₁₀—C₁₋₅ alkoxy, R₁′—C(O)—C₁₋₅ alkyl and R₁₂—C₁₋₅ alkyl(R₁₃)N;     -   cycloalkyl selected from the group consisting of cyclopropyl,         cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, wherein the         cycloalkyl is optionally partially or fully halogenated and         optionally substituted with one to three C₁₋₃ alkyl groups;     -   C₁₋₆alkoxycarbonylC₁₋₆alkyl;         or R₁ and R₂ taken together optionally form a fused phenyl or         pyridinyl ring;         each R₈ and R₁₃ is independently selected from the group         consisting of: hydrogen and C₁₋₄ branched or unbranched alkyl         optionally partially or fully halogenated; and         each R₄, R₅, R₆, R₇, R₉, R₁₀, R₁ ₁ and R₁₂ is independently         selected from the group consisting of morpholine, piperidine,         piperazine, imidazole and tetrazole;         wherein X is directly attached to one —Y-Z.

In yet another preferred embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein:

-   Ar₁ is pyrazole; -   X is:     -   cyclopentenyl, cyclohexenyl, cycloheptenyl, optionally         substituted with an oxo group or one to three C₁₋₄ alkyl, C₁₋₄         alkoxy or C₁₋₄ alkylamino chains each being branched or         unbranched;     -   phenyl, furanyl, thienyl, pyridinyl, pyrazinyl piperidinyl or         pyrimidinyl each being optionally independently substituted with         one to three C₁₋₂ alkyl, C₁₋₂alkoxy, hydroxy or halogen; -   Z is:     -   phenyl, heteroaryl selected from pyridinyl, imidazolyl and         furanyl, heterocycle selected from         2-oxa-5-aza-bicyclo[2.2.1]heptanyl, pentamethylene sulfidyl,         pentamethylene sulfoxidyl, pentamethylene sulfonyl,         tetrahydrofuranyl, tetrahydropyranyl, piperazinyl, morpholino,         thiomorpholino, thiomorpholino sulfoxide and piperidinyl, each         of the aforementioned Z are optionally substituted with one to         three halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₃alkoxy-C₁₋₃ alkyl,         C₁₋₆ alkoxycarbonyl, aroyl, morpholinocarbonyl, C₁₋₃acyl, oxo,         hydroxy, pyridinyl-C₁₋₃ alkyl, imidazolyl-C₁₋₃ alkyl,         tetrahydrofuranyl-C₁₋₃ alkyl, nitrile-C₁₋₃ alkyl, nitrile,         carboxy, phenyl wherein the phenyl ring is optionally         substituted with one to two halogen, C₁₋₆ alkoxy, hydroxy or         mono- or di-(C₁₋₃ alkyl)amino, amino-S(O)_(m), C₁₋₆         alkyl-S(O)_(m), or phenyl-S(O)_(m) wherein the phenyl ring is         optionally substituted with one to two halogen, C₁₋₆ alkoxy,         hydroxy, halogen or mono- or di-(C₁₋₃ alkyl)amino;     -   or Z is optionally substituted with one to three amino,         aminocarbonyl or amino-C-₁₋₃ alkyl wherein the N atom is         optionally independently mono- or di-substituted by         aminoC₁₋₆alkyl, C₁₋₃alkyl, arylC₀₋₃alkyl, C₁₋₅ alkoxyC₁₋₃ alkyl,         C₁₋₅ alkoxy, aroyl, C₁₋₃acyl, C₁₋₃alkyl-S(O)_(m)—,         pyridinylC₀₋₃alkyl, tetrahydrafuranylC₀₋₃alkyl, or         arylC₀₋₃alkyl-S(O)_(m)— each of the aforementioned alkyl and         aryl attached to the amino group is optionally substituted with         one to two halogen, C₁₋₆ alkyl or C₁₋₆ alkoxy;     -   or Z is hydroxy, hydroxyC₁₋₃alkyl, halogen, nitrile, amino         wherein the N atom is optionally independently mono- or         di-substituted by C₁₋₆alkyl, pyridinylC₀₋₃alkyl,         tetrahydrafuranylC₀₋₃alkyl, C₁₋₅ alkoxyC₁₋₃ alkyl, C₁₋₃acyl,         nitrileC₁₋₄alkyl or phenyl wherein the phenyl ring is optionally         substituted with one to two halogen, C₁₋₆ alkoxy, hydroxy or         mono- or di-(C₁₋₃ alkyl)amino,     -   or Z is C₁₋₆alkyl branched or unbranched, C₁₋₆alkoxy or         nitrileC₁₋₄alkyl; -   R₁ is:     -   C₁₋₄ branched or unbranched alkyl optionally partially or fully         halogenated;     -   cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl and         cycloheptanyl optionally partially or fully halogenated and         optionally substituted with one to three C₁₋₃ alkyl groups, or         an analog of such cycloalkyl group wherein one to three ring         methylene groups are replaced by groups independently selected         from the group consisting of O, S and NH;     -   C₃₋₁₀ branched alkenyl optionally partially or fully halogenated         and optionally substituted with one to three C₁₋₃ branched or         unbranched alkyl; cyclopentenyl and cyclohexenyl optionally         substituted with one to three C₁₋₃alkyl groups; -   R₂ is:     -   a C₁₋₆ branched or unbranched alkyl optionally partially or         fully halogenated and optionally substituted with nitrile; -   R₃ is:     -   phenyl or heterocyclic group selected from the group consisting         of pyridinyl, pyrimidinyl, pyridazinyl and pyrazolyl, wherein         such phenyl or heterocyclic group is optionally substituted with         one to five groups selected from the group consisting of a         phenyl, heterocycle selected from the group hereinabove         described in this paragraph, C₁₋₆ branched or unbranched alkyl         which is optionally partially or fully halogenated, phenyl C₁₋₅         alkyl, halogen, hydroxy, oxo, nitrile, C₁₋₃ alkoxy optionally         partially or fully halogenated, C₁₋₃thioalkyl,         C₁₋₃thioalkylC₁₋₅alkyl, amino, mono- or di-(C₁₋₃) alkylamino,         NH₂C(O) or a mono- or di-(C₁₋₃)alkyl aminocarbonyl,     -   C₁₋₆alkoxycarbonylC₁₋₆alkyl;     -   or R₃ is cyclopropyl or cyclopentyl each optionally partially or         fully halogenated and optionally substituted with one to three         C₁₋₃ alkyl groups         or R₁ and R₂ taken together optionally form a fused phenyl or         pyridinyl ring.

In yet still another preferred embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein:

-   Y is —CH₂—, —O—(CH₂)₀₋₃—, —CH₂CH₂—, —CH₂NH—, —CH₂CH₂—NH—,     NH—CH₂CH₂—, —CH₂—NH—CH₂—, —NH—, —NH—C(O)—, —C(O)—, —CH(OH)—,     —CH₂(CH₂CH₃)— or a bond; -   X is:     -   cyclohexenyl optionally substituted with an oxo group or one to         three C₁₋₄ alkyl, C₁₋₄ alkoxy or C₁₋₄ alkylamino chains each         being branched or unbranched;     -   phenyl, pyridinyl, pyrazinyl, piperidinyl or pyrimidinyl each         being optionally independently substituted with one to three         C₁₋₂ alkyl, C₁₋₂alkoxy, hydroxy or halogen; -   Z is:     -   phenyl, heteroaryl selected from pyridinyl, imidazolyl and         furanyl, heterocycle selected from         2-oxa-5-aza-bicyclo[2.2.1]heptanyl, pentamethylene sulfidyl,         pentamethylene sulfoxidyl, pentamethylene sulfonyl,         tetrahydrofuranyl, tetrahydropyranyl, piperazinyl, morpholino,         thiomorpholino, thiomorpholino sulfoxide and piperidinyl, each         of the aforementioned Z are optionally substituted with one to         three halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₃ alkoxy-C₁₋₃ alkyl,         C₁₋₆ alkoxycarbonyl, aroyl, morpholinocarbonyl, C₁₋₃acyl, oxo,         hydroxy, pyridinyl-C₁₋₃ alkyl, imidazolyl-C₁₋₃ alkyl,         tetrahydrofuranyl-C₁₋₃ alkyl, nitrile-C₁₋₃ alkyl, nitrile,         carboxy, phenyl wherein the phenyl ring is optionally         substituted with one to two halogen, C₁₋₆ alkoxy, hydroxy or         mono- or di-(C₁₋₃ alkyl)amino, amino-S(O)_(m), C₁₋₆         alkyl-S(O)_(m), or phenyl-S(O)_(m) wherein the phenyl ring is         optionally substituted with one to two halogen, C₁₋₆ alkoxy,         hydroxy, halogen or mono- or di-(C₁₋₃ alkyl)amino;     -   or Z is optionally substituted with one to three amino or         aminocarbonyl wherein the N atom is optionally independently         mono- or di-substituted by aminoC₁₋₆alkyl, C₁₋₃alkyl,         arylC₀₋₃alkyl, C₁₋₅ alkoxyC₁₋₃ alkyl, C₁₋₅ alkoxy, aroyl,         C₁₋₃acyl, C₁₋₃alkyl-S(O)_(m)— or arylC₀₋₃alkyl-S(O)_(m)— each of         the aforementioned alkyl and aryl attached to the amino group is         optionally substituted with one to two halogen, C₁₋₆ alkyl or         C₁₋₆ alkoxy;     -   or Z is hydroxy, hydroxyC₁₋₃alkyl, halogen, nitrile, amino         wherein the N atom is optionally independently mono- or         di-substituted by C₁₋₃alkyl, pyridinylC₁₋₂alkyl,         tetrahydrafuranylC₁₋₂alkyl, C₁₋₃ alkoxyC₁₋₃ alkyl, C₁₋₃acyl,         nitrileC₁₋₄alkyl, phenyl wherein the phenyl ring is optionally         substituted with one to two halogen, C₁₋₆ alkoxy, hydroxy or         mono- or di-(C₁₋₃ alkyl)amino,         or Z is C₁₋₆alkyl branched or unbranched, C₁₋₆alkoxy or         nitrileC₁₋₄alkyl; -   R₁ is:     -   C₁₋₄ branched or unbranched alkyl optionally partially or fully         halogenated; -   R₂ is:     -   a C₁₋₃ branched or unbranched alkyl optionally partially or         fully halogenated and optionally substituted with nitrile; -   R₃ is:     -   phenyl or heterocyclic group selected from the group consisting         of pyridinyl, pyrimidinyl, and pyrazolyl, wherein such phenyl or         heterocyclic group is optionally substituted with one to five         groups selected from the group consisting of C₁₋₃ branched or         unbranched alkyl which is optionally partially or fully         halogenated, C₁₋₃ alkoxy which optionally partially or fully         halogenated, C₁₋₃thioalkyl, C₁₋₃thioalkylC₁₋₅alkyl, amino or         NH₂C(O);     -   C₁₋₃alkoxycarbonyl;     -   or R₃ is cyclopropyl or cyclopentyl each optionally partially or         fully halogenated and optionally substituted with one to three         C₁₋₃ alkyl groups.

In a further embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein:

-   Ar₁ is 5-tert-butyl-pyrazol-3-yl; wherein the pyrazole ring is     substituted independently by one to two R₂ or R₃; -   X is:     -   cyclohexenyl;     -   phenyl, pyridinyl, pyrazinyl, piperidinyl or pyrimidinyl each         being optionally independently substituted with C₁₋₂alkoxy or         hydroxy; -   Z is:     -   phenyl, heteroaryl selected from pyridinyl and furanyl,         heterocycle selected from 2-oxa-5-aza-bicyclo[2.2.1]heptanyl,         pentamethylene sulfidyl, pentamethylene sulfoxidyl,         tetrahydrofuranyl, piperazinyl, morpholino, thiomorpholino and         piperidinyl, each of the aforementioned Z are optionally         substituted with one to three C₁₋₃ alkyl, C₁₋₃ alkoxy, oxo,         hydroxy or NH₂C(O)—;     -   or Z is hydroxyC₁₋₃alkyl, amino wherein the N atom is optionally         independently mono- or di-substituted by pyridinylmethyl,         tetrahydrafuranylmethyl, C₁₋₃ alkoxyC₁₋₃ alkyl, C₁₋₃acyl or         nitrileC₁₋₄alkyl,         or Z is nitrileC₁₋₄alkyl; -   R₃ is:     -   phenyl or heterocyclic group selected from the group consisting         of pyridinyl, pyrimidinyl, and pyrazolyl, wherein such phenyl or         heterocyclic group is optionally substituted with one to two         groups selected from the group consisting of C₁₋₂ alkyl which is         optionally partially or fully halogenated, C₁₋₂ alkoxy which         optionally partially or fully halogenated, C₁₋₂thioalkyl,         C₁₋₂thioalkylC₁₋₃alkyl, amino or NH₂C(O);     -   C₁₋₃alkoxycarbonyl;     -   or R₃ is cyclopropyl or cyclopentyl each optionally partially or         fully halogenated and optionally substituted with one to three         C₁₋₃ alkyl groups.

In another preferred embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein X is pyridinyl.

In another preferred embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein the pyridinyl is attached to Ar₁ via the 3-pyridinyl position.

The following compounds are preferred compounds of the p38 kinase inhibitors which can be used in the methods described herein:

-   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-morpholin-4-yl-methylphenyl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[3-(4-morpholin-4-yl-methylphenyl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(5-morpholin-4-yl-methylfuran-2-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(morpholin-4-yl-methyl)cyclohexenyl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(4-morpholin-4-yl)ethylphenyl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-dimethylaminomethylphenyl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(5-(morpholin-4-yl-methyl)pyridin-2-yl)-aphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-methyl-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(2-(morpholin-4-yl)ethylamino)cyclohexenyl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3,4-(morpholin-4-yl-methyl)phenyl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-methylpiperzin-1-yl-methyl)phenyl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(piperdin-1-yl-methyl)phenyl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(2-(pyridin-2-yl)ethylamino)cyclohexenyl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(2-(pyridin-4-yl)ethylaminomethyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(pyridin-3-yl-methylaminomethyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(3,4-dimethoxyphenylmethyl)-3-hydroxyphenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-oxo-1,6-dihydro-pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(morpholin-4-yl-methyl)phenyl)     naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(morpholin-4-yl-methyl)imidazol-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(morpholin-4-yl-methyl)imidazol-1-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(furan-3-yl-methyl)-3-hydroxyphenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(4-hydroxybutylamino)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(pyridin-3-yl-methyl)-3-hydroxyphenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(4-methyl-3-carbamylphenyl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(imidazol-2-yl-methyl)-3-hydroxyphenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(3-hydroxyrnorpholin-4-yl-methyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(N-2-methoxyethy-N-methylaminomethyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(4-hydroxymorpholin-4-yl-methyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(morpholin-4-yl-methyl)cyclohexenyl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(tetrahydrofuran-3-yl-methyl)-3-hydroxyphenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(N,N-di-(2-methoxyethyl)aminomethyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(3-cyanopropoxy)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-morpholin-4-yl-methyl-piperdinyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(N,N-di-(2-cyanoethyl)aminomethyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(1-morpholin-4-yl-indan-5-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(furan-2-yl-methyl)-3-hydroxyphenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(thiomorpholin-4-yl-methyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(3-carboxamidomorpholin-4-yl-methyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(2-methyl-3-oxo-piperzin-1-yl-methyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(4-hydroxybutyloxy)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[3-tert-butyl-1′H-[1,4′]bipyrazol-5-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(furan-2-yl-methyl)-3-methoxyphenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(5-(morpholin-4carbonyl)pyrazin-2-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(tetrahydrothiopyran-4-yl-amino)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-cyanoethyl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(2,6-dimethylmorpholin-4-yl-methyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methoxypyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-aminoypyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-oxo-1,6-dihydropyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-4-carbonyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl-methyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(3-carbamylphenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(N-(2-cyanoethyl)-N-(pyridin-3-yl-methyl)aminomethyl)phenyl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(N-(2-cyanoethyl)-N-(pyridin-2-yl-methyl)aminomethyl)phenyl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(N-(2-cyanoethyl)-N-(tetrahydrofuran-2-yl-methyl)aminomethyl)phenyl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)-4-methoxypyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(1-morpholin-4-yl-propyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(N-(3-methoxypropyl)amino)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(N-(3-methoxypropyl)-N-methylamino)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[3-tert-butyl-1′-methyl-1′H-[1,4′]bipyrazol-5-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-benzyl-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(N—N-di-(2-cyanoethyl)aminomethyl)phenyl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(4-carbamylphenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(1-oxo-tetrahydrothiopyran-4yl-amino)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(tetrahydropyran-4yl-amino)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[3-tert-butyl-1′-(3-cyanopropyl)-1′H-[1,4′]bipyrazol-5-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-methanesulfinylphenyl)naphthalen-1-yl]urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-methanesulfonylphenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-sulfonamidophenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(morpholin-4-yl)carbonylphenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(5-(tetrahydrothiopyran-4yl-amino)pyrazin-2-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(methylcarbonylamino)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-4-carbonyl)phenyl)-naphthalen-1-yl]-urea; -   1-[3-tert-butyl-1′-(3-methylsulfanylpropyl)-1′H-[1,4′]bipyrazol-5-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(5-(morpholin-4-yl-carbonyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(5-(morpholin-4-yl-methyl)pyrazin-2-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-aminopyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(1-methylpiperdin-4-yl-amino)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(2-methyl-3-oxo-piperzin-1-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-carbonyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(N,N-di-(2-methoxyethyl)aminomethyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(1-oxo-thiomorpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(tetrahydropyran-4-yl-amino)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(5-(morpholin-4-yl-methyl)pyrazin-2-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylthiopyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(2-methyl-3-oxo-piperzin-1-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(pyridin-3-yl-oxy)pyridin-3-yl)naphthalen-1-yl]-urea -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(pyridin-3-yl-amino)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methoxypyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(5-carbamylpyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-aminopyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(4-(morpholin-4-yl-methyl)     phenyl)naphthalen-1-yl]-urea; -   1-[3-tert-butyl-1′-methyl-1′H-[1,4′]bipyrazol-5-yl]-3-[4-(6-(morpholin-4-yl-methyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-cyclopropylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(pyridin-3-yl-amino)pyrimidin-5-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(1-oxo-tetrahydrothiopyran-4-yl-amino)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(thiomorpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-benzyl-3H-imidazo[4,5-b]pyridin-6-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(pyridin-3-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(morpholin-4-yl-carbonyl)pyrimidin-5-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(morpholin-4-yl-methyl)pyrimidin-5-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-amino-4-carbamylphenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(1-oxo-thiomorpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(pyridin-3-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(hydroxy-pyridin-3-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-(morpholin-4-yl-methyl)pyrimidin-5-yl)naphthalen-1-yl]-urea;     and the pharmaceutically acceptable derivatives thereof.

The following compounds are more preferred compounds of the p38 kinase inhibitors which can be used in the methods described herein:

-   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(5-(morpholin-4-yl-methyl)pyridin-2-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(2-(pyridin-2-yl)ethylamino)cyclohexenyl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(pyridin-3-yl-methylaminomethyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(morpholin-4-yl-methyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(4-hydroxybutylamino)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(4-methyl-3-carbamylphenyl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(3-hydroxypiperidin-1-yl-methyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(4-hydroxymorpholin-4-yl-methyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(morpholin-4-yl-methyl)cyclohexenyl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(tetrahydrofuran-3-yl-methyl)-3-hydroxyphenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(N,N-di-(2-methoxyethyl)aminomethyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(3-cyanopropoxy)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-morpholin-4-yl-methyl-piperdinyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(N,N-di-(2-cyanoethyl)aminomethyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(furan-2-yl-methyl)-3-hydroxyphenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(thiomorpholin-4-yl-methyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(3-carboxamidopiperidin-1-yl-methyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(2-methyl-3-oxo-piperzin-1-yl-methyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(4-hydroxybutyloxy)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[3-tert-butyl-1′H-[1,4′]bipyrazol-5-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(tetrahydrothiopyran-4-yl-amino)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-cyanoethyl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(2,6-dimethylmorpholin-4-yl-methyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methoxypyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-aminoypyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-4-carbonyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(2-oxa-5-aza-bicyclo     [2.2.1]hept-5-yl-methyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(N-(2-cyanoethyl)-N-(pyridin-3-yl-methyl)aminomethyl)phenyl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(N-(2-cyanoethyl)-N-(tetrahydrofuran-2-yl-methyl)aminomethyl)phenyl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)-4-methoxypyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(1-morpholin-4-yl-propyl)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[3-tert-butyl-1′-methyl-1′H-[1,4′]bipyrazol-5-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(1-oxo-tetrahydrothiopyran-4yl-amino)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(tetrahydropyran-4yl-amino)pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(5-(tetrahydrothiopyran-4yl-amino)pyrazin-2-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(methylcarbonylamino)     pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[3-tert-butyl-1′-(3-methylsulfanylpropyl)-1′H-[1,4′]bipyrazol-5-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(1-oxo-thiomorpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(tetrahydropyran-4-yl-amino)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylthiopyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-aminopyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[3-tert-butyl-1′-methyl-1′H-[1,4′]bipyrazol-5-yl]-3-[4-(6-(morpholin-4-yl-methyl)phenyl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(1-oxo-tetrahydrothiopyran-4-yl-amino)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(thiomorpholin-4-yl-methyl)pyridin-3-yl)     naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(morpholin-4-yl-carbonyl)pyrimidin-5-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(morpholin-4-yl-methyl)pyrimidin-5-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(1-oxo-thiomorpholin-4-yl-methyl)pyridin-3-yl)naphthalen-1-yl]-urea; -   1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-(morpholin-4-yl-methyl)pyrimidin-5-yl)naphthalen-1-yl]-urea     and     the pharmaceutically acceptable derivatives thereof.

In another preferred embodiment the invention provides a method of anticoagulant and fibrinolytic therapy for a disease or condition relating to blood coagulation or fibrinolysis comprising administering to a patient in need thereof a pharmaceutically effective a amount of a p38 MAP kinase inhibitor chosen from the compounds of formula (II) disclosed in WO 00/55139 and corresponding U.S. Pat. No. 6,358,945:

wherein:

-   G is:     -   an aromatic C₆₋₁₀ carbocycle or a nonaromatic C₃₋₁₀ carbocycle         saturated or unsaturated;     -   a 6-10 membered heteroaryl containing 1 or more heteroatoms         chosen from O, N and S;     -   a 5-8 membered monocyclic heterocycle containing one or more         heteroatoms chosen from O, N and S;     -   or     -   an 8-11 membered bicyclic heterocycle, containing one or more         heteroatoms chosen from O, N and S;     -   wherein G is substituted by one or more R₁, R₂ or R₃; -   Ar is:     -   phenyl, naphthyl, quinolinyl, isoquinolinyl, tetrahydronaphthyl,         tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzimidazolyl,         benzofuranyl, dihydrobenzofuranyl, indolinyl, benzothienyl,         dihydrobenzothienyl, indanyl, indenyl or indolyl each being         optionally substituted by one or more R₄ or R₅; -   X is:     -   a C₅₋₈ cycloalkyl or cycloalkenyl optionally substituted with         one to two oxo groups or one to three C₁₋₄ alkyl, C₁₋₄ alkoxy or         C₁₋₄ alkylamino chains;     -   phenyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl,         pyridinyl, pyrimidinyl, pyridinonyl, dihydropyridinonyl,         maleimidyl, dihydromaleimidyl, piperdinyl, benzimidazole,         3H-imidazo[4,5-b]pyridine, piperazinyl, pyridazinyl or         pyrazinyl; -   Y is:     -   a bond or a C₁₋₄ saturated or unsaturated branched or unbranched         carbon chain optionally partially or fully halogenated, wherein         one or more methylene groups are optionally replaced by O, N, or         S(O)_(m) and wherein Y is optionally independently substituted         with one to two oxo groups, phenyl or one or more C₁₋₄ alkyl         optionally substituted by one or more halogen atoms; -   Z is:     -   phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl,         imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl,         pyranyl each being optionally substituted with one to three         halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, amino, mono- or         di-(C₁₋₃ alkyl)amino, C₁₋₆ alkyl-S(O)_(m), CN, CONH₂, COOH or         phenylamino wherein the phenyl ring is optionally substituted         with one to two halogen, C₁₋₆ alkyl or C₁₋₆ alkoxy;         tetrahydropyranyl, tetrahydrofuranyl, 1,3-dioxolanonyl,         1,3-dioxanonyl, 1,4-dioxanyl, morpholinyl, thiomorpholinyl,         thiomorpholino sulfoxidyl, thiomorpholino sulfonyl, piperidinyl,         piperidinonyl, piperazinyl, tetrahydropyrimidonyl,         cyclohexanonyl, cyclohexanolyl, pentamethylene sulfidyl,         pentamethylene sulfoxidyl, pentamethylene sulfonyl,         tetramethylene sulfide, tetramethylene sulfoxidyl or         tetramethylene sulfonyl each being optionally substituted with         one to three nitrile, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, amino,         mono- or di-(C₁₋₃ alkyl)amino-C₁₋₃ alkyl, CONH₂,         phenylamino-C₁₋₃ alkyl or C₁₋₃ alkoxy-C₁₋₃ alkyl;     -   halogen, C₁₋₄ alkyl, nitrile, amino, hydroxy, C₁₋₆ alkoxy,         NH₂C(O), mono- or di(C₁₋₃alkyl) aminocarbonyl, mono- or         di(C₁₋₆alkyl)amino, secondary or tertiary amine wherein the         amino nitrogen is covalently bonded to C₁₋₃ alkyl or C₁₋₅         alkoxyalkyl, pyridinyl-C₁₋₃ alkyl, imidazolyl-C₁₋₃ alkyl,         tetrahydrofuranyl-C₁₋₃ alkyl, nitrile-C-₁₋₃ alkyl,         carboxamide-C₁₋₃ alkyl, phenyl, wherein the phenyl ring is         optionally substituted with one to two halogen, C₁₋₆ alkoxy,         hydroxy or mono- or di-(C₁₋₃ alkyl)amino, C₁₋₆ alkyl-S(O)_(m),         or phenyl-S(O)_(m), wherein the phenyl ring is optionally         substituted with one to two halogen, C₁₋₆ alkoxy, hydroxy,         halogen or mono- or di-(C₁₋₃ alkyl)amino; C₁₋₆ alkyl-S(O)_(m),         and phenyl-S(O)_(m), wherein the phenyl ring is optionally         substituted with one to two halogen, C₁₋₆ alkoxy, hydroxy or         mono- or di-(C₁₋₃ alkyl)amino;         each R₁ is independently:     -   C₁₋₁₀ alkyl optionally be partially or fully halogenated, and         optionally substituted with one to three C₃₋₁₀ cycloalkanyl,         hydroxy, phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl,         pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,         isoxazolyl or isothiazolyl; each of the aforementioned being         optionally substituted with one to five groups selected from         halogen, C₁₋₆ alkyl which is optionally partially or fully         halogenated, C₃₋₈ cycloalkanyl, C₅₋₈ cycloalkenyl, hydroxy,         nitrile, C₁₋₃ alkoxy which is optionally partially or fully         halogenated or NH₂C(O), mono- or di(C₁₋₃alkyl)amino, and mono-         or di(C₁₋₃alkyl)aminocarbonyl;     -   cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, or         cycloheptyloxy each being optionally partially or fully         halogenated and optionally substituted with one to three C₁₋₃         alkyl groups optionally partially or fully halogenated, CN,         hydroxyC₁₋₃alkyl or aryl; or an analog of such cycloalkyl group         wherein one to three ring methylene groups are independently         replaced by O, S(O)_(m), CHOH, >C═O, >C═S or NH;     -   phenyloxy or benzyloxy each being optionally partially or fully         halogenated and optionally substituted with one to three C₁₋₃         alkyl groups optionally partially or fully halogenated, CN,         hydroxyC₁₋₃alkyl or aryl; or an analog of such cycloaryl group         wherein one to two ring methyne groups are independently         replaced by N;     -   cyclopropanyl, cyclobutanyl, cyclopentanyl, cyclohexanyl,         cycloheptanyl, bicyclopentanyl, bicyclohexanyl or         bicycloheptanyl, each being optionally partially or fully         halogenated and optionally substituted with one to three C₁₋₃         alkyl groups optionally partially or fully halogenated, CN,         hydroxyC₁₋₃alkyl or aryl; or an analog of such cycloalkyl group         wherein one to three ring methylene groups are independently         replaced by O, S(O)_(m), CHOH, >C═O, >C═S or NH;     -   C₃₋₁₀ branched or unbranced alkenyl each being optionally         partially or fully halogenated, and optionally be substituted         with one to three C₁₋₅ branched or unbranched alkyl, phenyl,         naphthyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,         pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl or         isothiazolyl, each of the aforementioned being substituted with         zero to five halogen, C₁₋₆ alkyl which is optionally partially         or fully halogenated, cyclopropanyl, cyclobutanyl,         cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl,         bicyclohexanyl and bicycloheptanyl, hydroxy, nitrile, C₁₋₃         alkyloxy which is optionally partially or fully halogenated,         NH₂C(O), mono- or di(C₁₋₃alkyl)aminocarbonyl; the C₃₋₁₀ branched         or unbranced alkenyl being optionally interrupted by one or more         heteroatoms chosen from O, N and S(O)_(m);     -   cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,         cycloheptadienyl, bicyclohexenyl or bicycloheptenyl, wherein         such cycloalkenyl group is optionally substituted with one to         three C₁₋₃ alkyl groups;     -   nitrile, halogen;     -   methoxycarbonyl, ethoxycarbonyl and propoxycarbonyl;     -   silyl containing three C₁₋₄ alkyl groups optionally partially or         fully halogenated;     -   C₃₋₆ alkynyl branched or unbranched carbon chain optionally         partially or fully halogenated, wherein one or more methylene         groups are optionally replaced by O, NH or S(O)_(m) and wherein         said alkynyl group is optionally independently substituted with         one to two oxo groups, pyrrolidinyl, pyrrolyl, one or more C₁₋₄         alkyl optionally substituted by one or more halogen atoms,         nitrile, morpholino, piperidinyl, piperazinyl, imidazolyl,         phenyl, pyridinyl, tetrazolyl, or mono- or di(C₁₋₃alkyl)amino         optionally substituted by one or more halogen atoms;         each R₂, R₄, and R₅ is     -   a C₁₋₆ branched or unbranched alkyl optionally partially or         fully halogenated, acetyl, aroyl, C₁₋₄ branched or unbranched         alkoxy, each being optionally partially or fully halogenated,         halogen, nitrile, methoxycarbonyl, C₁₋₃ alkyl-S(O)_(m)         optionally partially or fully halogenated, or phenylsulfonyl;     -   C₁₋₆ alkoxy, hydroxy, amino, or mono- or di-(C₁₋₄ alkyl)amino,         nitrile, halogen;     -   OR₆;     -   nitro; or     -   mono- or di-(C₁₋₄ alkyl)amino-S(O)₂ optionally partially or         fully halogenated, or H₂NSO₂;         each R₃ is independently:     -   phenyl, naphthyl, morpholinyl, pyridinyl, pyrimidinyl,         pyrazinyl, pyridazinyl, pyrrolyl, pyrrolidinyl, imidazolyl,         pyrazolyl, thiazolyl, oxazoyl, triazolyl, tetrazolyl, thienyl,         furyl, tetrahydrofuryl, isoxazolyl, isothiazolyl, quinolinyl,         isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl,         benzoxazolyl, benzisoxazolyl, benzpyrazolyl, benzothiofuranyl,         cinnolinyl, pterindinyl, phthalazinyl, naphthypyridinyl,         quinoxalinyl, quinazolinyl, purinyl or indazolyl, each of the         aforementioned is optionally substituted with one to three         phenyl, naphthyl, heterocycle or heteroaryl as hereinabove         described in this paragraph, C₁₋₆ branched or unbranched alkyl         which is optionally partially or fully halogenated,         cyclopropanyl, cyclobutanyl, cyclopentanyl, cyclohexanyl,         cycloheptanyl, bicyclopentanyl, bicyclohexanyl, bicycloheptanyl,         phenyl C₁₋₅ alkyl, naphthyl C₁₋₅ alkyl, halogen, hydroxy, oxo,         nitrile, C₁₋₃ alkyloxy optionally partially or fully         halogenated, phenyloxy, naphthyloxy, heteroaryloxy or         heterocyclicoxy wherein the heterocyclic or heteroaryl moiety is         as hereinabove described in this paragraph, nitro, amino, mono-         or di-(C₁₋₃alkyl)amino, phenylamino, naphthylamino, heteroaryl         or heterocyclic amino wherein the heteroaryl heterocyclic moiety         is as hereinabove described in this paragraph, NH₂C(O), a mono-         or di-(C₁₋₃alkyl)aminocarbonyl, C₁₋₅ alkyl-C(O)—C₁₋₄ alkyl,         amino-C₁₋₅ alkyl, mono- or di-(C₁₋₃alkyl)amino-C₁₋₅ alkyl,         amino-S(O)₂, di-(C₁₋₃alkyl)amino-S(O)₂, R₇—C₁₋₅ alkyl, R₈—C₁₋₅         alkoxy, R₉—C(O)—C₁₋₅ alkyl, R₁₀—C₁₋₅ alkyl(R₁₁)N, carboxy-mono-         or di-(C₁₋₅alkyl)-amino;     -   a fused aryl selected from benzocyclobutanyl, indanyl, indenyl,         dihydronaphthyl, tetrahydronaphthyl, benzocycloheptanyl and         benzocycloheptenyl, or a fused heteroaryl selected from         cyclopentenopyridinyl, cyclohexanopyridinyl,         cyclopentanopyrimidinyl, cyclohexanopyrimidinyl,         cyclopentanopyrazinyl, cyclohexanopyrazinyl,         cyclopentanopyridazinyl, cyclohexanopyridazinyl,         cyclopentanoquinolinyl, cyclohexanoquinolinyl,         cyclopentanoisoquinolinyl, cyclohexanoisoquinolinyl,         cyclopentanoindolyl, cyclohexanoindolyl,         cyclopentanobenzimidazolyl, cyclohexanobenzimidazolyl,         cyclopentanobenzoxazolyl, cyclohexanobenzoxazolyl,         cyclopentanoimidazolyl, cyclohexanoimidazolyl,         cyclopentanothienyl and cyclohexanothienyl; wherein the fused         aryl or fused heteroaryl ring is independently substituted with         zero to three phenyl, naphthyl, pyridinyl, pyrimidinyl,         pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl,         thienyl, furyl, isoxazolyl, isothiazolyl, C₁₋₆ alkyl which is         optionally partially or fully halogenated, halogen, nitrile,         C₁₋₃ alkyloxy which is optionally partially or fully         halogenated, phenyloxy, naphthyloxy, heteroaryloxy or         heterocyclicoxy wherein the heteroaryl or heterocyclic moiety is         as hereinabove described in this paragraph, nitro, amino, mono-         or di-(C₁₋₃alkyl)amino, phenylamino, naphthylamino, heteroaryl         or heterocyclic amino wherein the heteroaryl or heterocyclic         moiety is as hereinabove described in this paragraph, NH₂C(O),         mono- or di-(C₁₋₃alkyl)aminocarbonyl, C₁₋₄ alkyl-OC(O), C₁₋₅         alkyl-C(O)—C₁₋₄ alkyl, amino-C₁₋₅ alkyl, mono- or         di-(C₁₋₃)alkylamino-C₁₋₅ alkyl, R₁₂—C₁₋₅ alkyl, R₁₃—C₁₋₅ alkoxy,         R₁₄—C(O)—C₁₋₅ alkyl or R₁₅—C₁₋₅ alkyl(R₁₆)N;     -   cyclopropanyl, cyclobutanyl, cyclopentanyl, cyclohexanyl,         cycloheptanyl, bicyclopentanyl, bicyclohexanyl or         bicycloheptanyl, each being optionally partially or fully         halogenated and optionally substituted with one to three C₁₋₃         alkyl groups, or an analog of such cycloalkyl group wherein one         to three ring methylene groups are independently replaced by O,         S, CHOH, >C═O, >C═S or NH;     -   cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl,         cycloheptadienyl, bicyclohexenyl or bicycloheptenyl, each         optionally substituted with one to three C₁₋₃ alkyl groups;     -   C₁₋₄ alkyl-phenyl-C(O)—C₁₋₄ alkyl-, C₁₋₄ alkyl-C(O)—C₁₋₄ alkyl-         or C₁₋₄ alkyl-phenyl-S(O)_(m)—C₁₋₄ alkyl-;     -   C₁₋₆ alkyl or C₁₋₆ branched or unbranched alkoxy each of which         is optionally partially or fully halogenated or optionally         substituted with R₁₇;     -   OR₁₈ or C₁₋₆ alkyl optionally substituted with OR₁₈;     -   amino or mono- or di-(C₁₋₅alkyl)amino optionally substituted         with R₁₉;     -   R₂OC(O)N(R₂₁)—, R₂₂O— or R₂₃R₂₄NC(O)—; R₂₆(CH₂)_(m)C(O)N(R₂₁)—         or R₂₆C(O)(CH₂)_(m)N(R₂₁)—;     -   C₂₋₆alkenyl substituted by R₂₃R₂₄NC(O)—;     -   C₂₋₆ alkynyl branched or unbranched carbon chain, optionally         partially or fully halogenated, wherein one or more methylene         groups are optionally replaced by O, NH, S(O)_(m) and wherein         said alkynyl group is optionally independently substituted with         one to two oxo groups, pyrroldinyl, pyrrolyl, morpholinyl,         piperidinyl, piperazinyl, imidazolyl, phenyl, pyridinyl,         tetrazolyl one or more C₁₋₄ alkyl optionally substituted by one         or more halogen atoms, nitrile, morpholino, piperidinyl,         piperazinyl, imidazolyl, phenyl, pyridinyl, tetrazolyl, or mono-         or di(C₁₋₄ alkyl)amino optionally substituted by one or more         halogen atoms; or     -   aroyl; -   R₆ is a:     -   C₁₋₄ alkyl optionally partially or fully halogenated and         optionally substituted with R₂₆;     -   each R₇, R₈, R₉, R₁₀, R₁₂, R₁₃, R₁₄, R₁₅, R₁₇, R₁₉, R₂₅ and R₂₆         is independently: nitrile, phenyl, morpholino, piperidinyl,         piperazinyl, imidazolyl, pyridinyl, tetrazolyl, amino or mono-         or di-(C₁₋₄alkyl)amino optionally partially or fully         halogenated; -   each R₁₁ and R₁₆ is independently:     -   hydrogen or C₁₋₄ alkyl optionally partially or fully         halogenated; -   R₁₈ is independently:     -   hydrogen or a C₁₋₄ alkyl optionally independently substituted         with oxo or R₂₅; -   R₂₀ is independently:     -   C₁₋₁₀alkyl optionally partially or fully halogenated, phenyl, or         pyridinyl; -   R₂₁ is independently:     -   hydrogen or C₁₋₃ alkyl optionally partially or fully         halogenated;         each R₂₂, R₂₃ and R₂₄ is independently: hydrogen, C₁₋₆ alkyl         optionally partially or fully halogenated, said C₁₋₆ alkyl is         optionally interrupted by one or more O, N or S, said C₁₋₆ alkyl         also being independently optionally substituted by mono- or         di-(C₁₋₃alkyl)aminocarbonyl, phenyl, pyridinyl, amino or mono-         or di-(C₁₋₄alkyl)amino each of which is optionally partially or         fully halogenated and optionally substituted with mono- or         di-(C₁₋₃alkyl)amino;         or R₂₃ and R₂₄ taken together optionally form a heterocyclic or         heteroaryl ring; -   m=0, 1 or 2; -   W is O or Sand     pharmaceutically acceptable derivatives thereof.

In a preferred embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein:

-   G is:     -   phenyl, naphthyl, benzocyclobutanyl, dihydronaphthyl,         tetrahydronaphthyl, benzocycloheptanyl, benzocycloheptenyl,         indanyl, indenyl;     -   pyridinyl, pyridonyl, quinolinyl, dihydroquinolinyl,         tetrahydroquinoyl, isoquinolinyl, tetrahydroisoquinoyl,         pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl,         benzthiazolyl, benzoxazolyl, benzofuranyl, benzothiophenyl,         benzpyrazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl,         benzooxazolonyl, benzo[1,4]oxazin-3-onyl, benzodioxolyl,         benzo[1,3]dioxol-2-onyl, benzofuran-3-onyl,         tetrahydrobenzopyranyl, indolyl, indolinyl, indolonyl,         indolinonyl, phthalimidyl; oxetanyl, pyrrolidinyl,         tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl,         piperazinyl, morpholinyl, tetrahydropyranyl, dioxanyl,         tetramethylene sulfonyl, tetramethylene sulfoxidyl, oxazolinyl,         thiazolinyl, imidazolinyl, tertrahydropyridinyl,         homopiperidinyl, pyrrolinyl, tetrahydropyrimidinyl,         decahydroquinolinyl, decahydroisoquinolinyl, thiomorpholinyl,         thiazolidinyl, dihydrooxazinyl, dihydropyranyl, oxocanyl,         heptacanyl, thioxanyl or dithianyl;     -   wherein G is substituted by one or more R₁, R₂ or R₃;

In another preferred embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein:

-   G is phenyl, pyridinyl, pyridonyl, naphthyl, quinolinyl,     isoquinolinyl, pyrazinyl, benzimidazolyl, benzoxazolyl,     benzofuranyl, benzothiophenyl, benzpyrazolyl, dihydrobenzofuranyl,     dihydrobenzothiophenyl, indanyl, indenyl, indolyl, indolinyl,     indolonyl or indolinonyl, wherein G is substituted by one or more     R₁, R₂ or R₃; -   Ar is:     -   naphthyl, quinolinyl, isoquinolinyl, tetrahydronaphthyl,         tetrahydroquinolinyl, tetrahydroisoquinolinyl, indanyl, indenyl         or indolyl each being optionally substituted by one or more R₄         or R₅ groups; -   X is:     -   phenyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl,         pyridinyl, pyrimidinyl, pyridinonyl, dihydropyridinonyl,         maleimidyl, dihydromaleimidyl, piperdinyl, piperazinyl,         pyridazinyl or pyrazinyl -   Y is:     -   a bond or     -   a C₁₋₄ saturated or unsaturated carbon chain wherein one of the         carbon atoms is optionally replaced by O, N, or S(O)_(m) and         wherein Y is optionally independently substituted with one to         two oxo groups, phenyl or one or more C₁₋₄ alkyl optionally         substituted by one or more halogen atoms; -   Z is:     -   phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl,         imidazolyl, furanyl, thienyl, dihydrothiazolyl, dihydrothiazolyl         sulfoxidyl, pyranyl, pyrrolidinyl which are optionally         substituted with one to three nitrile, C₁₋₃ alkyl, C₁₋₃ alkoxy,         amino, mono- or di-(C₁₋₃ alkyl)amino, CONH₂ or OH;     -   tetrahydropyranyl, tetrahydrofuranyl, 1,3-dioxolanonyl,         1,3-dioxanonyl, 1,4-dioxanyl, morpholinyl, thiomorpholinyl,         thiomorpholino sulfoxidyl, piperidinyl, piperidinonyl,         piperazinyl, tetrahydropyrimidonyl, pentamethylene sulfidyl,         pentamethylene sulfoxidyl, pentamethylene sulfonyl,         tetramethylene sulfidyl, tetramethylene sulfoxidyl or         tetramethylene sulfonyl which are optionally substituted with         one to three nitrile, C₁₋₃ alkyl, C₁₋₃ alkoxy, amino, mono- or         di-(C₁₋₃ alkyl)amino, CONH₂, or OH; nitrile, C₁₋₆         alkyl-S(O)_(m), halogen, hydroxy, C₁₋₄ alkoxy, amino, mono- or         di-(C₁₋₆ alkyl)amino, mono- or di-(C₁₋₃ alkyl)aminocarbonyl or         NH₂C(O);         each R₁ is independently:     -   C₃₋₆ alkyl optionally partially or fully halogenated, and         optionally substituted with one to three C₃₋₆cycloalkyl, phenyl,         thienyl, furyl, isoxazolyl or isothiazolyl; each of the         aforementioned being optionally substituted with one to three         groups selected from halogen, C₁₋₃ alkyl which is optionally         partially or fully halogenated, hydroxy, nitrile or C₁₋₃alkoxy         which is optionally partially or fully halogenated;     -   cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl,         bicyclopentanyl or bicyclohexanyl, each being optionally         partially or fully halogenated and optionally substituted with         one to three C₁₋₃alkyl groups optionally partially or fully         halogenated, CN, hydroxyC₁₋₃alkyl or phenyl; or an analog of         such cycloalkyl group wherein one to three ring methylene groups         are independently replaced by O, S, CHOH, >C═O, >C═S or NH; or     -   silyl containing three C₁₋₄ alkyl groups optionally partially or         fully halogenated; -   R₂ is independently:     -   halogen, C₁₋₃ alkoxy, C₁₋₃ alkyl-S(O)_(m) optionally partially         or fully halogenated, phenylsulfonyl or nitrile; -   R₃ is independently:     -   phenyl, morpholino, pyridinyl, pyrimidinyl, pyrazinyl, pyrrolyl,         pyrrolylidinyl, imidazolyl, pyrazolyl, each being optionally         substituted with one to three phenyl, naphthyl, heterocycle or         heteroaryl as hereinabove described in this paragraph, C₁₋₆         alkyl which is optionally partially or fully halogenated,         cyclopropanyl, cyclobutanyl, cyclopentanyl, cyclohexanyl,         cycloheptanyl, bicyclopentanyl, bicyclohexanyl, bicycloheptanyl,         phenyl C₁₋₅ alkyl, naphthyl C₁₋₅ alkyl, halogen, oxo, hydroxy,         nitrile, C₁₋₃ alkyloxy optionally partially or fully         halogenated, phenyloxy, naphthyloxy, heteroaryloxy or         heterocyclicoxy wherein the heteroaryl or heterocyclic moiety is         as hereinabove described in this paragraph, nitro, amino, mono-         or di-(C₁₋₃alkyl)amino, phenylamino, naphthylamino, heteroaryl         or heterocyclic amino wherein the heteroaryl or heterocyclic         moiety is as hereinabove described in this paragraph, NH₂C(O), a         mono- or di-(C₁₋₃alkyl)aminocarbonyl, C₁₋₅ alkyl-C(O)—C₁₋₄         alkyl, mono- or di-(C₁₋₃alkyl)amino, mono- or         di-(C₁₋₃)alkylamino-C₁₋₅ alkyl, mono- or         di-(C₁₋₃alkyl)amino-S(O)₂, R₇—C₁₋₅ alkyl, R₈—C₁₋₅ alkoxy,         R₉—C(O)—C₁₋₅ alkyl, R₁₀—C₁₋₅ alkyl(R₁)N, carboxy-mono- or         di-(C₁₋₅)-alkyl-amino;     -   C₁₋₃ alkyl or C₁₋₄ alkoxy each being optionally partially or         fully halogenated or optionally substituted with R₁₇;     -   OR₁₈ or C₁₋₆ alkyl optionally substituted with OR₁₈;     -   amino or mono- or di-(C₁₋₅ alkyl)amino optionally substituted         with R₁₉;     -   R₂OC(O)N(R₂₁)—, R₂₂O—; R₂₃R₂₄NC(O)—; R₂₆CH₂C(O)N(R₂₁)— or         R₂₆C(O)CH₂N(R₂₁)—;     -   C₂₋₄alkenyl substituted by R₂₃R₂₄NC(O)—; or     -   C₂₋₄ alkynyl branched or unbranched carbon chain optionally         partially or fully halogenated and optionally independently         substituted with one to two oxo groups, pyrroldinyl, pyrrolyl,         morpholinyl, piperidinyl, piperazinyl, imidazolyl, phenyl,         pyridinyl, tetrazolyl or one or more C₁₋₄ alkyl optionally         substituted by one or more halogen atoms; and -   R₂₃ and R₂₄ taken together optionally form imidazolyl, piperidinyl,     morpholinyl, piperazinyl or a pyridinyl ring.

In yet another preferred embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein:

-   G is phenyl, pyridinyl, pyridonyl, naphthyl, quinolinyl,     isoquinolinyl, pyrazinyl, benzothiophenyl, dihydrobenzofuranyl,     dihydrobenzothiophenyl, indanyl, indolyl, indolinyl, indolonyl or     indolinonyl, wherein G is substituted by one or more R₁, R₂ or R₃; -   Ar is naphthyl; -   X is     -   phenyl, imidazolyl, pyridinyl, pyrimidinyl, piperdinyl,         piperazinyl, pyridazinyl or pyrazinyl each being optionally         independently substituted with one to three C₁₋₄ alkyl,         C₁₋₄alkoxy, hydroxy, nitrile, amino, mono- or di-(C₁₋₃         alkyl)amino, mono- or di-(C₁₋₃ alkylamino)carbonyl, NH₂C(O),         C₁₋₆ alkyl-S(O)_(m) or halogen; -   Y is:     -   a bond or     -   a C₁₋₄ saturated carbon chain wherein one of the carbon atoms is         optionally replaced by O, N or S and wherein Y is optionally         independently substituted with an oxo group; -   Z is:     -   phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl,         imidazolyl, dihydrothiazolyl, dihydrothiazolyl sulfoxide,         pyranyl or pyrrolidinyl which are optionally substituted with         one to two C₁₋₂ alkyl or C₁₋₂ alkoxy;     -   tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiomorpholino         sulfoxidyl, piperidinyl, piperidinonyl, piperazinyl or         tetrahydropyrimidonyl which are optionally substituted with one         to two C₁₋₂ alkyl or C₁₋₂ alkoxy; or     -   C₁₋₃ alkoxy; -   each R₁ is independently:     -   C₃₋₅ alkyl optionally partially or fully halogenated, and         optionally substituted with phenyl substituted with zero to         three halogen, C₁₋₃ alkyl which is optionally partially or fully         halogenated, hydroxy, nitrile or C₁₋₃alkoxy which is optionally         partially or fully halogenated;     -   cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl,         bicyclopentanyl or bicyclohexanyl, each being optionally         partially or fully halogenated and optionally substituted with         one to three C₁₋₃ alkyl groups optionally partially or fully         halogenated, CN, hydroxyC₁₋₃alkyl or phenyl; and an analog of         cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl,         bicyclopentanyl or bicyclohexanyl wherein one ring methylene         group is replaced by O; and     -   silyl containing three C₁₋₂ independently alkyl groups         optionally partially or fully halogenated;         each R₂ is independently:     -   bromo, chloro, fluoro, methoxy, methylsulfonyl or nitrile;         each R₃ is independently:     -   phenyl, morpholino, pyridinyl, pyrimidinyl, pyrrolylidinyl,         2,5-pyrrolidin-dionyl, imidazolyl, pyrazolyl, each of the         aforementioned is optionally substituted with one to three C₁₋₃         alkyl which is optionally partially or fully halogenated,         halogen, oxo, hydroxy, nitrile and C₁₋₃ alkyloxy optionally         partially or fully halogenated;     -   C₁₋₃ alkyl or C₁₋₃ alkoxy each being optionally partially or         fully halogenated or optionally substituted with R₁₇;     -   OR₁₈ or C₁₋₃ alkyl optionally substituted with OR₁₈;     -   amino or mono- or di-(C₁₋₃ alkyl)amino optionally substituted         with R₁₉;     -   R₂₀C(O)N(R₂₁)13 , R₂₂O—; R₂₃R₂₄NC(O)—; R₂₆CH₂C(O)N(R₂₁)— or         R₂₆C(O)CH₂N(R₂₁)—;     -   C₂₋₄ alkenyl substituted by R₂₃R₂₄NC(O)—; or     -   C₂₋₄ alkynyl substituted with pyrroldinyl or pyrrolyl;         and -   R₂₃ and R₂₄ taken together optionally form morpholino.

In yet still another preferred embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein:

-   G is phenyl, pyridinyl, pyridonyl, naphthyl, quinolinyl,     isoquinolinyl, dihydrobenzofuranyl, indanyl, indolinyl, indolonyl,     or indolinonyl, wherein G is substituted by one or more R₁, R₂ or     R₃; -   Ar is 1-naphthyl; -   X is:     -   phenyl, imidazolyl, pyridinyl, pyrimidinyl, piperdinyl,         piperazinyl, pyridazinyl or pyrazinyl; -   Y is:     -   a bond or     -   —CH₂—, —CH₂CH₂—, —C(O)—, —O—, —S—, —NH—CH₂CH₂CH₂—, —N(CH₃)—, or         —NH—;         each R₁ is independently:     -   C₃₋₅ alkyl optionally partially or fully halogenated, and         optionally substituted with phenyl;     -   cyclopropyl, cyclopentanyl, cyclohexanyl and bicyclopentanyl         optionally substituted with one to three methyl groups         optionally partially or fully halogenated, CN, hydroxymethyl or         phenyl; or 2-tetrahydrofuranyl substituted by methyl; or         trimethyl silyl;         each R₃ is independently:     -   phenyl, morpholinyl, pyridinyl, pyrimidinyl, pyrrolylidinyl,         2,5-pyrrolidin-dionyl, imidazolyl or pyrazolyl, wherein any of         the aforementioned is optionally substituted with C₁₋₂ alkyl         which is optionally partially or fully halogenated;     -   C₁₋₃ alkyl or C₁₋₃ alkoxy each being optionally partially or         fully halogenated or optionally substituted with diethylamino;     -   OR₁₈ or C₁₋₃ alkyl optionally substituted with OR₁₈;     -   amino or mono- or di-(C₁₋₃ alkyl)amino optionally substituted         with R₁₉;     -   CH₃C(O)NH—, R₂₂O—; R₂₃R₂₄NC(O)—; R₂₆CH₂C(O)N(R₂₁)— or         R₂₆C(O)CH₂N(R₂₁)—;     -   C₂₋₄alkenyl substituted by R₂₃R₂₄NC(O)—; or C₂₋₄ alkynyl         substituted with pyrroldinyl or pyrrolyl; -   R₂₃ and R₂₄ are H or R₂₃ and R₂₄ taken together optionally form     morpholino; and R₂₆ is morpholino.

In a further embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein:

-   G is     -   phenyl, pyridinyl or naphthyl wherein G is substituted by one or         more R₁, R₂ or R₃; -   X is:     -   imidazolyl or pyridinyl; -   Y is:     -   —CH₂—, —NH—CH₂CH₂CH₂— or —NH—; -   Z is morpholino; each R₁ is independently:     -   tert-butyl, sec-butyl, tert-amyl or phenyl; -   R₂ is chloro; -   R₃ is independently:     -   methyl, methoxy, methoxymethyl, hydroxypropyl, acetamide,         morpholino or morpholinocarbonyl.

In another preferred embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein X is pyridinyl.

In another preferred embodiment the p38 kinase inhibitor is selected from the compounds as immediately described above and wherein the pyridinyl is attached to Ar via the 3-pyridinyl position.

The following compounds are preferred compounds of the p38 kinase inhibitors which can be used in the methods described herein:

-   1-(3-Cyano-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(3-Fluoro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(4-Chloro-2-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2-Chloro-5-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(3,4-Dimethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(3-Iodo-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-m-tolyl-urea -   1-(4-Methylsulfanyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(3-Chloro-4-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(4-Chloro-3-nitro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2,5-Dichloro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-naphthalen-2-yl-urea -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-phenyl-urea -   1-(3-Chloro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(4-Chloro-3-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(2,4,6-trichloro-phenyl)-urea -   1-(2-Methyl-3-nitro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(4-Methyl-2-nitro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2,3-Dichloro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2-Methoxy-5-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2-Chloro-6-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2,4-Dichloro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(4-Methyl-3-nitro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2,4-Dimethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2,3-Dimethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(4-Cyano-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(3,4,5-trimethoxy-phenyl)-urea -   1-Biphenyl-4-yl-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2,5-Difluoro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(3-Chloro-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2-Fluoro-3-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(4-Benzyloxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2-Methylsulfanyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2-Fluoro-6-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(4-Fluoro-3-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(2,4,5-trimethyl-phenyl)-urea -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(4-trifluoromethyl-phenyl)-urea -   1-(3-Methylsulfanyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2-Methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2-Fluoro-5-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(4-Methoxy-2-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2-Fluoro-5-nitro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(4-Ethoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2,5-Dimethoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(4,5-Dimethyl-2-nitro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(5-Chloro-2-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2-Isopropyl-6-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2-Difluoromethoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(4-Isopropyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(4-Methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(3-Ethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2-Ethoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(4-Butoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   4-{3-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-benzoic     acid ethyl ester -   1-(4-Butyl-2-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2,6-Dibromo-4-isopropyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(3-Methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(4-trifluoromethylsulfanyl-phenyl)-urea -   5-{3-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-isophthalic     acid dimethyl ester -   1-(3-Cyclopentyloxy-4-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   3-{3-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-benzoic     acid ethyl ester -   1-(5-tert-Butyl-2-hydroxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2-Hydroxymethyl-4-phenyl-cyclohexyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2-Methylsulfanyl-5-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(4-pentyloxy-biphenyl-3-yl)-urea -   4-Methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-benzoic     acid methyl ester -   1-(2,5-Diethoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-Benzothiazol-6-yl-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-y)-naphthalen-1-yl]-urea -   N-(2,5-Diethoxy-4-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-benzamide -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(3-phenoxy-phenyl)-urea -   1-(5-Ethanesulfonyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   4-Methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-N-phenyl-benzamide -   1-(2-Methyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2,3-Dimethyl-1H-indol-5-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   N-Butyl-4-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-benzenesulfonamide -   1-[3-(2-Methyl-[1,3]dioxolan-2-yl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(3-Methoxy-5-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2,4-Dimethoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2-Methyl-4-nitro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2-Methoxy-4-nitro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(4-Chloro-2-nitro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(5-Chloro-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(3,5-Dimethoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(4-trifluoromethoxy-phenyl)-urea -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(3-trifluoromethylsulfanyl-phenyl)-urea -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(2-phenoxy-phenyl)-urea -   1-(2-Methoxy-5-nitro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(3,5-Bis-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(2-tert-Butyl-5-methyl-pyridin-4-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(3-Methyl-naphthalen-2-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(3-tert-Butyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(4-Methyl-biphenyl-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(4-tert-Butyl-biphenyl-2-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(5-Isopropyl-2-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(5-sec-Butyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(5-tert-Butyl-2-methoxy-3-propyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(5-tert-Butyl-2-methoxymethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(5-tert-Butyl-2-methyl-phenyl)-3-(4-{6-[(3-methoxy-propyl)-methyl-amino]-pyridin-3-yl}-naphthalen-1-yl)-urea -   1-(5-tert-Butyl-2-methyl-phenyl)-3-[4-(4-morpholin-4-ylmethyl-imidazol-1-yl)-naphthalen-1-yl]-urea -   1-(5-tert-Butyl-2-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(5-tert-Butyl-2-methyl-phenyl)-3-{4-[6-(3-methoxy-propylamino)-pyridin-3-yl]-naphthalen-1-yl}-urea -   1-(5-tert-Butyl-2-methyl-pyridin-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(5-tert-Butyl-2-morpholin-4-yl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-(6-tert-Butyl-2-chloro-3-methyl-pyridin-4-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(3-trifluoromethyl-phenyl)-urea -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(4-trifluoromethoxy-phenyl)-urea -   1-[5-(1,1-Dimethyl-propyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-[5-tert-Butyl-2-(1H-pyrazol-4-yl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-[5-tert-Butyl-2-(2-methyl-pyrimidin-5-yl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-[5-tert-Butyl-2-(3-hydroxy-propyl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-[5-tert-Butyl-2-(3-morpholin-4-yl-3-oxo-propyl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   1-[5-tert-Butyl-2-(morpholine-4-carbonyl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea -   N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-acetamide -   1-(2-tert-Butyl-5-methyl-pyridin-4-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(3-Methyl-naphthalen-2-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(3-tert-Butyl-phenyl)-3-[4-(4-morpholin-4-ylmethyl-phenyl)-naphthalen-1-yl]-urea; -   1-(3-tert-Butyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(4-Methyl-biphenyl-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(4-tert-Butyl-biphenyl-2-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-Isopropyl-2-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-sec-Butyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-3-propyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxymethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-morpholin-4-ylmethyl-pyrimidin-5-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(4-thiomorpholin-4-ylmethyl-phenyl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-phenyl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[4-(tetrahydro-pyran-4-ylamino)-phenyl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(4-methyl-piperazin-1-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methyl-phenyl)-3-(4-{6-[(3-methoxy-propyl)-methyl-amino]-pyridin-3-yl}-naphthalen-1-yl)-urea; -   1-(5-tert-Butyl-2-methyl-phenyl)-3-[4-(4-morpholin-4-ylmethyl-imidazol-1-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methyl-phenyl)-3-[4-(4-morpholin-4-ylmethyl-phenyl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methyl-phenyl)-3-{4-[6-(3-methoxy-propylamino)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methyl-pyridin-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-morpholin-4-yl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(6-tert-Butyl-2-chloro-3-methyl-pyridin-4-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(6-tert-Butyl-2-chloro-3-methyl-pyridin-4-yl)-3-[4-(6-thiomorpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[2-Methoxy-5-(1-methyl-cyclopropyl)-phenyl]-3-[4-(2-morpholin-4-ylmethyl-pyrimidin-5-yl)-naphthalen-1-yl]-urea; -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(3-trifluoromethyl-phenyl)-urea; -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(4-trifluoromethoxy-phenyl)-urea; -   1-[5-(1,1-Dimethyl-propyl)-2-methoxy-phenyl]-3-[4-(4-thiomorpholin-4-ylmethyl-phenyl)-naphthalen-1-yl]-urea; -   1-[5-(1,1-Dimethyl-propyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-(1-Cyano-cyclopropyl)-2-methoxy-phenyl]-3-[4-(2-morpholin-4-ylmethyl-pyrimidin-5-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-(1H-pyrazol-4-yl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-(2-methyl-pyrimidin-5-yl)-phenyl]-3-[4-(5-pyridin-4-ylmethyl-pyridin-2-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-(2-methyl-pyrimidin-5-yl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-(3-hydroxy-propyl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-5     1-yl]-urea; -   1-[5-tert-Butyl-2-(3-morpholin-4-yl-3-oxo-propyl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-(morpholine-4-carbonyl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   2-[4-tert-Butyl-2-(3-{4-[6-(2,6-dimethyl-morpholin-4-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-ureido)-phenoxy]-acetamide; -   3-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-1-yl}-benzamide; -   4-tert-Butyl-2-{3-[4-(2-chloro-4-morpholin-4-ylmethyl-phenyl)-naphthalen-1-yl]-ureido}-benzamide;     and the pharmaceutically acceptable derivatives thereof.

The following compounds are more preferred compounds of the p38 kinase inhibitors which can be used in the methods described herein:

-   1-(2-tert-Butyl-5-methyl-pyridin-4-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(3-tert-Butyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(4-Methyl-biphenyl-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(4-tert-Butyl-biphenyl-2-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-Isopropyl-2-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-sec-Butyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxymethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methyl-phenyl)-3-(4-{6-[(3-methoxy-propyl)-methyl-amino]-pyridin-3-yl}-naphthalen-1-yl)-urea; -   1-(5-tert-Butyl-2-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methyl-pyridin-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-(1,1-Dimethyl-propyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-(1H-pyrazol-4-yl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-(2-methyl-pyrimidin-5-yl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-(3-hydroxy-propyl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-(morpholine-4-carbonyl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-acetamide     and the pharmaceutically acceptable derivatives thereof.

The following compounds are more preferred compounds of the p38 kinase inhibitors which can be used in the methods described herein:

-   1-(4-tert-Butyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methyl-phenyl)-3-[4-(4-morpholin-4-ylmethyl-piperidin-1-yl)-naphthalen-1-yl]-urea; -   1-(6-Chloro-4-trifluoromethyl-pyridin-2-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(4-Difluoromethoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(3-Methyl-naphthalen-2-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[2-Methoxy-5-(1-methyl-1-phenyl-ethyl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   (5-tert-Butyl-2-methyl-phenyl)-carbamic acid     3-(5-{4-[3-(5-tert-butyl-2-methyl-phenyl)-ureido]-naphthalen-1-yl}-pyridin-2-ylamino)-propyl     ester; -   1-(6-tert-Butyl-benzo[1,3]dioxol-5-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-acetamide; -   1,3-Bis-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-3-(2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-2-hydroxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-3-(2,3-dihydroxy-propyl)-2-hydroxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(2,3-Dimethyl-1H-indol-5-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(2-p-tolyloxy-5-trifluoromethyl-phenyl)-urea; -   1-[2-(2-Methoxy-phenoxy)-5-trifluoromethyl-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-naphthalen-1-yl-urea; -   1-{5-tert-Butyl-2-methyl-3-[3-(tetrahydro-pyran-2-yloxy)-prop-1-ynyl]-phenyl}-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-{5-tert-Butyl-2-[3-(tetrahydro-pyran-2-yloxy)-prop-1-ynyl]-phenyl}-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-Hydroxymethyl-2-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(2-Methoxy-dibenzofuran-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(2,5-Di-tert-butyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[3-(4-Bromo-1-methyl-1H-pyrazol-3-yl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(3-Hydroxy-5,6,7,8-tetrahydro-naphthalen-2-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(1-Acetyl-2,3-dihydro-1H-indol-5-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(3-oxazol-5-yl-phenyl)-urea; -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(3-[1,3,4]oxadiazol-2-yl-phenyl)-urea; -   1-(2-Methoxy-5-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   Furan-2-carboxylic acid     (4-tert-butyl-2-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-amide; -   1-(2-Methoxy-4-phenylamino-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-Methoxy-2-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(3-Hydroxy-naphthalen-2-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   N,N-Diethyl-4-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-benzenesulfonamide; -   1-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-(1,1-Dimethyl-propyl)-2-phenoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-(2,2-Dimethyl-propionyl)-2-methyl-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   2-Chloro-5-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-benzoic     acid isopropyl ester; -   1-(4-Amino-3,5-dibromo-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-3-(3-hydroxy-prop-1-ynyl)-2-methyl-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-(3-hydroxy-prop-1-ynyl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-3-(2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-3-(2,3-dihydroxy-propyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butoxy-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-(1-Cyano-cyclopropyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-3-(2-diethylamino-ethyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-[1,3]dioxolan-2-yl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-pyrrolidin-1-yl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-dimethylamino-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-propoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-hydroxymethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(2,6-dimethyl-morpholin-4-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   2-(5-tert-Butyl-2-methoxy-phenyl)-N-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-acetamide; -   1-(2-Methoxy-5-phenoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-7-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-cyclopentyloxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(3-pyridin-3-yl-pyrrolidin-1-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-Cyclohexyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(2,4-Dimethoxy-5-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(6-tert-Butyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-7-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-3-nitro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-3-[4-(6-methyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   N-Acetyl-N-(5-tert-butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-acetamide; -   1-(6-tert-Butyl-4-methyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[6-tert-Butyl-4-(2-morpholin-4-yl-ethyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-ethoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-isopropoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-imidazol-1-yl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   N-(5-tert-Butyl-2-methoxy-4-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide; -   1-(5-tert-Butyl-3-ethylamino-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-bis(methanesulfon)amide; -   1-[5-tert-Butyl-2-(1-methyl-1H-pyrazol-4-yl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(2-Methanesulfinyl-5-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(2-Ethanesulfonyl-5-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[4-(6-{[Bis-(2-methoxy-ethyl)-amino]-methyl}-pyridin-3-yl)-naphthalen-1-yl]-3-(5-tert-butyl-2-methoxy-phenyl)-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(3-dimethylamino-pyrrolidin-1-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   N-[1-(5-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-1-yl}-pyridin-2-ylmethyl)-pyrrolidin-3-yl]-acetamide; -   1-(1-Acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-5-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-propionamide; -   1-(5-tert-Butyl-2-methyl-benzooxazol-7-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(3-trifluoromethanesulfonyl-phenyl)-urea; -   N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-isobutyramide; -   2-(4-tert-Butyl-2-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenoxy)-acetamide; -   1-(5-tert-Butyl-2-oxo-2,3-dihydro-benzooxazol-7-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(6-tert-Butyl-3-cyano-2-methoxymethoxy-pyridin-4-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(6-tert-Butyl-3-cyano-2-hydroxy-pyridin-4-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-3-cyano-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(1,3,3-trimethyl-2,3-dihydro-1H-indol-5-yl)-urea; -   1-(5-tert-Butyl-benzooxazol-7-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-benzenesulfonamide; -   Ethanesulfonic acid     (5-tert-butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-amide; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(4-morpholin-4-ylmethyl-piperidin-1-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-(1-methyl-1H-pyrazol-4-yl)-phenyl]-3-[4-(4-morpholin-4-ylmethyl-piperidin-1-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-morpholin-4-ylmethyl-pyrimidin-5-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methylsulfanyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-pyridin-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   2,2,2-Trifluoro-ethanesulfonic acid     (5-tert-butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-amide; -   N-(5-{4-[3-(5-tert-Butyl-2-methyl-phenyl)-ureido]-naphthalen-1-yl}-pyrazin-2-yl)-methanesulfonamide; -   1-[4-(6-{[Bis-(2-cyano-ethyl)-amino]-methyl}-pyridin-3-yl)-naphthalen-1-yl]-3-(5-tert-butyl-2-methoxy-phenyl)-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(4-methyl-piperazin-1-ylmethyl)-pyridin-3-yl]naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-thiomorpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(2,6-dimethyl-piperidin-1-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(1-oxo-tetrahydro-thiopyran-4-ylamino)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(tetrahydro-pyran-4-ylamino)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-{[(2-cyano-ethyl)-(tetrahydro-furan-2-ylmethyl)-amino]-methyl}-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(2-methoxymethyl-morpholin-4-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{6-[(2-morpholin-4-yl-ethylamino)-methyl]-pyridin-3-yl}-naphthalen-1-yl)-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(2-methyl-3-oxo-piperazin-1-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-1-yl}-pyridin-2-ylmethyl)-piperidine-3-carboxylic     acid amide; -   1-(5-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-1-yl}-pyridin-2-ylmethyl)-piperidine-4-carboxylic     acid amide; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(1-oxo-114-thiomorpholin-4-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(3-oxo-piperazin-1-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-{4-[6-(4-Acetyl-piperazin-1-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-3-(5-tert-butyl-2-methoxy-phenyl)-urea; -   4-(5-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-1-yl}-pyridin-2-ylmethyl)-piperazine-1-carboxylic     acid ethyl ester; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{6-[(2-pyridin-3-yl-ethylamino)-methyl]-pyridin-3-yl}-naphthalen-1-yl)-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{6-[(tetrahydro-furan-3-ylamino)-methyl]-pyridin-3-yl}-naphthalen-1-yl)-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-{[(2-cyano-ethyl)-pyridin-3-ylmethyl-amino]-methyl}-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{6-[(2-methylsulfanyl-ethylamino)-methyl]-pyridin-3-yl}-naphthalen-1-yl)-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(2,6-dimethyl-morpholin-4-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{6-[(2-piperazin-1-yl-ethylamino)-methyl]-pyridin-3-yl}-naphthalen-1-yl)-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(4-pyrimidin-2-yl-piperazin-1-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(4-pyridin-2-yl-piperazin-1-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{6-[4-(3-methoxy-phenyl)-piperazin-1-ylmethyl]-pyridin-3-yl}-naphthalen-1-yl)-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(morpholine-4-carbonyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(2-thia-5-aza-bicyclo[2.2.1]hept-5-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(5-morpholin-4-ylmethyl-pyrazin-2-yl)-naphthalen—yl]-urea; -   1-(6-tert-Butyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   N-(5-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-1-yl}-pyridin-2-yl)-acetamide; -   N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-N-methyl-acetamide; -   N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-2,2,2-trifluoro-acetamide; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(pyridin-3-yloxy)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(pyridin-3-ylamino)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   [4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-carbamic     acid 3-tert-butyl-phenyl ester; -   N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]ureido}-phenyl)-methanesulfonamide     and     and the pharmaceutically acceptable derivatives thereof.

The following compounds are more preferred compounds of the p38 kinase inhibitors which can be used in the methods described herein:

-   1-(3-Methyl-naphthalen-2-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-acetamide; -   1-[5-tert-Butyl-3-(2,3-dihydroxy-propyl)-2-hydroxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(2,3-Dimethyl-1H-indol-5-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-{5-tert-Butyl-2-methyl-3-[3-(tetrahydro-pyran-2-yloxy)-prop-1-ynyl]-phenyl}-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(2-Methoxy-5-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-(2,2-Dimethyl-propionyl)-2-methyl-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-3-(3-hydroxy-prop-1-ynyl)-2-methyl-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-2-(3-hydroxy-prop-1-ynyl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-3-(2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-3-(2,3-dihydroxy-propyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butoxy-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-(1-Cyano-cyclopropyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[5-tert-Butyl-3-(2-diethylamino-ethyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-[1,3]dioxolan-2-yl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-pyrrolidin-1-yl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-dimethylamino-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-propoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-hydroxymethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(2,6-dimethyl-morpholin-4-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-Cyclohexyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(2,4-Dimethoxy-5-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-3-nitro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-3-[4-(6-methyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   N-Acetyl-N-(5-tert-butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-acetamide; -   1-(6-tert-Butyl-4-methyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-ethoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-isopropoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-imidazol-1-yl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-3-ethylamino-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-bis(methanesulfon)amide; -   1-[5-tert-Butyl-2-(1-methyl-1H-pyrazol-4-yl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(2-Methanesulfinyl-5-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[4-(6-{[Bis-(2-methoxy-ethyl)-amino]-methyl}-pyridin-3-yl)-naphthalen-1-yl]-3-(5-tert-butyl-2-methoxy-phenyl)-urea; -   N-[1-(5-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-1-yl}-pyridin-2-ylmethyl)-pyrrolidin-3-yl]-acetamide; -   1-(1-Acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-5-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-propionamide; -   1-(5-tert-Butyl-2-methyl-benzooxazol-7-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(3-trifluoromethanesulfonyl-phenyl)-urea; -   N-(5-tert-Butyl-2-methoxy-3-{3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-isobutyramide; -   2-(4-tert-Butyl-2-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenoxy)-acetamide; -   1-(5-tert-Butyl-2-oxo-2,3-dihydro-benzooxazol-7-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-3-cyano-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-benzooxazol-7-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-benzenesulfonamide; -   Ethanesulfonic acid     (5-tert-butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-amide; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-morpholin-4-ylmethyl-pyrimidin-5-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methylsulfanyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-pyridin-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   2,2,2-Trifluoro-ethanesulfonic acid     (5-tert-butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-amide; -   N-(5-{4-[3-(5-tert-Butyl-2-methyl-phenyl)-ureido]-naphthalen-1-yl}-pyrazin-2-yl)-methanesulfonamide; -   1-[4-(6-{[Bis-(2-cyano-ethyl)-amino]-methyl}-pyridin-3-yl)-naphthalen-1-yl]-3-(5-tert-butyl-2-methoxy-phenyl)-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(4-methyl-piperazin-1-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-thiomorpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(2,6-dimethyl-piperidin-1-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(1-oxo-tetrahydro-thiopyran-4-ylamino)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(tetrahydro-pyran-4-ylamino)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-{[(2-cyano-ethyl)-(tetrahydro-furan-2-ylmethyl)-amino]-methyl}-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(2-methoxymethyl-morpholin-4-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(2-methyl-3-oxo-piperazin-1-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-1-yl}-pyridin-2-ylmethyl)-piperidine-3-carboxylic     acid amide; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(1-oxo-114-thiomorpholin-4-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(3-oxo-piperazin-1-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{6-[(tetrahydro-furan-3-ylamino)-methyl]-pyridin-3-yl}-naphthalen-1-yl)-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-{[(2-cyano-ethyl)-pyridin-3-ylmethyl-amino]-methyl}-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(2,6-dimethyl-morpholin-4-ylmethyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{6-[4-(3-methoxy-phenyl)-piperazin-1-ylmethyl]-pyridin-3-yl}-naphthalen-1-yl)-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(morpholine-4-carbonyl)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(5-morpholin-4-ylmethyl-pyrazin-2-yl)-naphthalen-1-yl]-urea; -   1-(6-tert-Butyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   1-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; -   N-(5-{4-[3-(S-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-1-yl}-pyridin-2-yl)-acetamide; -   N-(5-tert-Butyl-2-methoxy-3-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-N-methyl-acetamide; -   N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-2,2,2-trifluoro-acetamide; -   1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(pyridin-3-yloxy)-pyridin-3-yl]-naphthalen-1-yl}-urea; -   [4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-carbamic     acid 3-tert-butyl-phenyl ester; -   N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide     and     and the pharmaceutically acceptable derivatives thereof.

More preferred, the p38 kinase inhibitors are:

or the pharmaceutically acceptable salts thereof.

Particularily preferred, the p38 kinase inhibitors is:

and the pharmaceutically acceptable derivatives thereof.

Any reference to the abovementioned p38 kinase inhibitors include “pharmaceutically acceptable derivative” thereof which refers to any pharmaceutically acceptable salt or ester of a compound of this invention, or any other compound which, upon administration to a patient, is capable of providing (directly or indirectly) a p38 kinase inhibitor of this invention, a pharmacologically active metabolite or pharmacologically active residue thereof. A pharmacologically active metabolite shall be understood to mean any compound capable of being metabolized enzymatically or chemically. This includes, for example, hydroxylated or oxidized derivative p 38 compounds.

Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfuric, tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfuric and benzenesulfonic acids. Other acids, such as oxalic acid, while not themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of this invention and their pharmaceutically acceptable acid addition salts. Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N—(C₁-C₄ alkyl)₄ ⁺ salts.

In addition, the compounds of this invention include prodrugs of p38 compounds. Prodrugs include those compounds that, upon simple chemical transformation, are modified to produce compounds of the invention. Simple chemical transformations include hydrolysis, oxidation and reduction. Specifically, when a prodrug of this invention is administered to a patient, the prodrug may be transformed into a p38 kinase inhibitor compound thereby imparting the desired pharmacological effect.

For prophylactic or therapeutic use, the pharmaceutical p38 kinase inhibitor compounds according to the invention may be administered in any conventional dosage form in any conventional manner. Routes of administration include, but are not limited to, intravenously, intramuscularly, subcutaneously, intrasynovially, by infusion, sublingually, transdermally, orally, topically or by inhalation. The preferred modes of administration are oral and intravenous.

p38 kinase inhibitors according to the invention may be administered separately, or in a combination formulation with adjuvants that enhance stability of the inhibitors, facilitate administration of pharmaceutical compositions containing them in certain embodiments, provide increased dissolution or dispersion, increase inhibitory activity, provide adjunct therapy, and the like, including other active ingredients. For combination therapy with the drugs listed hereinbelow, advantageously, such combination therapies utilize lower dosages of the conventional therapeutics, thus avoiding possible toxicity and adverse side effects incurred when those agents are used as monotherapies. p38 kinase inhibitors may therefore be physically combined with the conventional therapeutics or other adjuvants into a single pharmaceutical composition. Regarding pharmaceutical compositions, reference may be made to Cappola et al.: U.S. patent application Ser. No. 09/902,822, PCT/US 01/21860 and U.S. provisional application No. 60/313,527, each incorporated by reference herein in their entirety. The optimum percentage (w/w) of a compound of the invention may vary and is within the purview of those skilled in the art.

As mentioned above, dosage forms of the compositions described herein include pharmaceutically acceptable carriers and adjuvants known to those of ordinary skill in the art. These carriers and adjuvants include, for example, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, buffer substances, water, salts or electrolytes and cellulose-based substances. Preferred dosage forms include, tablet, capsule, caplet, liquid, solution, suspension, emulsion, lozenges, syrup, reconstitutable powder, granule, suppository and transdermal patch. Methods for preparing such dosage forms are known (see, for example, H. C. Ansel and N. G. Popovish, Pharmaceutical Dosage Forms and Drug Delivery Systems, 5th ed., Lea and Febiger (1990)). Dosage levels and requirements are well-recognized in the art and may be selected by those of ordinary skill in the art from available methods and techniques suitable for a particular patient. p38 kinase inhibitor, in some embodiments, dosage levels range from about 1-1000 mg/dose for a 70 kg patient. Although one dose per day may be sufficient, up to 5 doses per day may be given. For oral doses, up to 2000 mg/day may be required. Reference in this regard may also be made to U.S. provisional application No. 60/339,249. As the skilled artisan will appreciate, lower or higher doses may be required depending on particular factors. For instance, specific dosage and treatment regimens will depend on factors such as the patient's general health profile, the severity and course of the patient's disorder or disposition thereto, and the judgment of the treating physician.

In another aspect the present invention relates to a pharmaceutical composition suitable for inhalation which contains one or more salts of a p38 kinase inhibitor, optionally in the form of their solvates or hydrates. The active substances may either be combined in a single preparation or contained in two separate formulations. Pharmaceutical compositions which contain the active p38 kinase inhibitor substances in a single preparation are preferred according to the invention.

Anticoagulant and Fibrinolytic Activity of P38 MAP Kinase Inhibitors

It has been found for the first time that p38 MAPK has a role in activation of coagulation, fibrinolysis and the vascular endothelium. The invention therefore provides a method of anticoagulant and fibrinolytic therapy for a disease or condition relating to blood coagulation or fibrinolysis comprising administering to a patient in need thereof a pharmaceutically effective a amount of a p38 MAP kinase inhibitor.

p38 MAP Kinase has been determined to have a role in the activation of the hemostatic mechanism in vivo. A possible explanation for the anticoagulant effect of p38 MAP kinase inhibitors is inhibition of tissue factor expression. Tissue factor is essential for activation of the coagulation system in this model of low grade endotoxemia ^(3,6), and p38 MAPK inhibition markedly diminished LPS-induced tissue factor expression by monocytic cells in vitro ⁹. Moreover, p38 MAPK activation also mediates tissue factor expression by endothelial cells stimulated with thrombin or vascular endothelial growth factor, and by vascular smooth muscle cells stimulated with thrombin ¹⁰⁻¹² Furthermore, and not mutually exclusive, the reduced 1L-6 concentrations in subjects treated with a preferred p38 MAP kinase inhibitor of the formula (III) may have contributed to the attenuated coagulant response, considering that IL-6 is an important mediator of coagulation activation by LPS in vivo ¹⁶.

Intravenous injection of LPS is associated with activation of the coagulation system, as reflected by a rise in the plasma concentrations of the prothrombin fragment F1+2. The effective dosage range for formula (III) is described in U.S. provisional application 60/339,249. High end dosing of formula (III) inhibited LPS-induced coagulation activation, both delaying and diminishing the increase in plasma F1+2 concentrations. Formula (III) had an even stronger inhibitory effect on activation of the fibrinolytic system p38 MAP kinase inhibitors also have an effect on endothelial cell activation, reflected by the plasma concentrations of sE-selectin and vWF ¹⁸⁻²⁰ Administration of LPS elicited profound increases in the plasma levels of sE-selectin and vWF, which were attenuated by high dose formula (III). p38 MAPK may play a direct role in signaling inflammatory effects into the interior of the vascular endothelium ^(10,11,21), including the expression of E-selectin on stimulated endothelial cells ^(22,23).

Methods of Therapeutic Use

p38 compounds have been discovered for the first time to be useful in anticoagulant and finbrinolytic or thrombolytic therapy. Anticoagulants are used in treating acute venous thrombosis and pulmonary embolism. Thrombosis can also occur if the form of cerebral arterial embolism from cardiac sources such as ventricular mural thrombi or atrial thrombi or from an atherosclerotic, partially stenosed carotid or vertebral artery, or peripheral or mesenteric arterial thrombosis.

These agents may also be useful in preventing or treating thrombosis during pregancy, hemorrhagic skin necrosis, preventing or treating acute or chronic disseminated intravascular coagulation (DIC), prevention of clot formation occuring from surgery, long bed rest or long periods of immobilization such as that which occurs during air travel.

An example of a condition where an inhibitor of coagulation would be useful prohylactically is in the prevention or treatment of deep vein thrombosis (DVT). Current therapy involves anticoagulation with heparin. Venous thrombosis or thromophlebitis is caused by the presence of thrombus within a superficial or deep vein and the accompanying inflammatory response in the vessel wall The factors that predispose to venous thrombosis include stasis, vascular damage, and hypercoagulability and may occur in patients having orthopedic surgical procedures, particularly those involving the hip or knee, or patients who undergo abdominal or thoracic operations. The prevalence of venous thrombosis is particularly high in patients with cancer of the pancreas, lungs, genitourinary tract, stomach, and breast. Risk of thrombosis is increased following trauma, such as fractures of the spine, pelvis, femur, and tibia. Immobilization, regardless of the underlying disease, is a major predisposing cause of venous thrombosis.

An example of a disease where an agent that inhibits the fibrinolytic pathway would be useful is fulminant meningococcemia. Fulminant meningococcemia is perhaps the most rapidly lethal form of septic shock. Fibrinolytic therapy may also be an available treatment for patients with massive pulmonary embolism and systemic hypotension and to restore the patency of acutely occluded peripheral and coronary arteries. Timely fibrinolytic therapy may reduce both myocardial damage and mortality following acute coronary occlusion. Fibrinolytic therapy may also be effective in acute thrombotic strokes, acute coronary occlusion, acute peripheral arterial occlusion, massive pulmonary embolism with severe hypoxemia and hypotension, axillary vein thrombosis, massive iliofemoral vein thrombosis, occluded arterial or venous cannulae, cardiomyopathy, and venoocclusive disease of the liver.

Also with the scope of the invention is the combination therapy of a p38 inhibitor and one or more other anticoagulant or fibrinolytic agents. These include recombinant tissue plasminogen activator (rtPA), streptokinase (SK), urokinase (UK), proUK, heparin, enoxoparin, dalteparin, coumarin anticoagulants, aspirin, dipyrimidamole, aggrennox, ticlopidine, clopidogrel (Plavix), abciximab, RheoPro, integrilin, aggrestat and the like. Particular dosages, formulations and methods of administration either alone or combined is within the skill in the art.

The Examples which follow serve to illustrate the present invention in more detail without restricting the scope of the invention to the following embodiments by way of example.

Inhibition of P38 MAP Kinase

To determine binding affinities for compounds to p38 MAP kinase, a fluorescence binding assay is used as described [Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S. & Regan, J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nature Structural Biology 9, 268-272 (2002)]. Binding studies are conducted in aqueous solutions prepared using binding buffer: 20 mM Bis-TRIS Propane (pH 7.0), 2 mM EDTA, 0.01% NaN₃, and 0.15% n-octylglucoside. Kinetic data for the association of SK&F 86002 to p38 MAP kinase is collected on a Kintech fluorescence detector system equipped with a stopped flow controller. The data is fit simultaneously to an appropriate equation describing kinetic binding for a simple 1-step binding mechanism [Morelock, M. M., Pargellis, C. A., Graham, E. T., Lamarre, D. & Jung, G. Time-resolved ligand exchange reactions: kinetic models for competitive inhibitors with recombinant human renin. J. Med. Chem. 38, 1751-1761 (1995)]. The exchange curve assays are run as two half reactions using an SLM Aminco Bowman Series 2 Model SQ-340 fluorescence detector. Preliminary equilibrium are set up with two half reactions differing in the order of addition of the two p38 MAP kinase inhibitors. In the first half reaction, p38 MAP kinase and SK&F 86002 are preincubated for 3 minutes. In the second half reaction p38 MAP kinase is preincubated with BIRB 796 for 60 minutes. A net dissociation of the fluorescent probe, SK&F 86002, is observed for the first half reaction and a net association is observed for the second half reaction. The raw data from both half reactions are fitted simultaneously to an equation describing simple competitive inhibition[Morelock, M. M., Pargellis, C. A., Graham, E. T., Lamarre, D. & Jung, G. Time-resolved ligand exchange reactions: kinetic models for competitive inhibitors with recombinant human renin. J. Med. Chem. 38, 1751-1761 (1995)]. BIRB 796 (chemical name: 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea) was synthesized as described [Cirillo, P., Gilmore, T. A., Hickey, E., Regan, J. & Zhang, L. H. Aromatic heterocyclic compounds as antiinflammatory agents. (WO0043384) Dec. 9, 1999].

Preferred compounds will have an IC₅₀<1 uM in this assay, confirming inhibition of p38 MAP Kinase.

EXAMPLE I Synthesis of Formula (III)

Formula (III), p38 inhibitor:

1-[3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea

All p38 MAP kinase inhibitors described herein may be prepared by the methods found in the citations provided herein and by methods known in the art. Formula (III) may be obtained as described in U.S. Pat. No. 6,319,921 or U.S. application Ser. No. 09/611,109.

5-Amino-3-t-butyl-1-p-tolylpyrazole hydrochloride: A solution of pivaloylacetonitrile (750 g, 6.0 mol) and p-tolylhydrazine hydrochloride (660 g, 4.2 mol) in methanol (2.8 L) was refluxed for 3 h. Heptane was added, and methanol was removed by distillation. The product was crystallized from the solution, collected by filtration and dried in vacuum oven to constant weight. Yield: 1.05 kg, 94%. ¹H NMR □CDCl₃) 7.50 (d, 2H), 7.30 (d, 2H), 5.60 (s, 1H), 2.45 (s, 3H), 1.40 (s, 9H). MS (CI) m/z 229 (M⁺+H).

5-(2,2,2-Trichloroethoxycarbonyl)amino-3-t-butyl-1-p-tolylpyrazole: A mixture of 5-amino-3-t-butyl-1-p-tolylpyrazole hydrochloride (300 g, 1.13 mol), water (0.9 L), EtOAc (2.1 L) and NaOH (117 g, 2.84 mol) was stirred between 5-15° C. for 30 min. To this mixture, 2,2,2-trichloroethyl chloroformate (342 g, 1.58 mol) was added over 1 h between 5-15° C. The mixture was stirred at room temperature for 2 h, and then the aqueous layer was separated from the EtOAc layer. The EtOAc layer was washed with brine (2×0.9 L) and dried over MgSO₄ (60 g). The EtOAc layer was collected by filtration. To this solution, heptane was added. A part of the solution was removed by distillation. The product was crystallized from the solution, collected by filtration and dried in vacuum oven to constant weight. Yield: 409 g, 90%. ¹H NMR (CDCl₃) 7.40 (d, 2H), 7.30 (d, 2H), 6.40 (s, 1H), 4.80 (s, 2H), 2.40 (s, 3H), 1.40 (s, 9H). MS (EI) m/z 404 (M⁺).

4-Nitro-1-(2-morpholinethoxy)naphthalene: A mixture of 4-nitro-1-hydroxynaphthalene (194 g, 1.0 mol), 4-(2-chloroethyl)morpholine hydrochloride (264 g, 1.4 mol), NaOH (58 g, 1.4 mol), K₂CO₃ (339 g, 2.4 mol) and 1-methyl-2-pyrrolidinone (1.0 L) was heated to 90-100° C. and held for 1-2 h. The mixture was cooled to 40° C. and water was slowly added. The mixture was cooled to 5° C. and held for 4 h. The product was collected by filtration, washed with water, cyclohexane and dried in vacuum to constant weight. Yield: 227 g, 75%. ¹H NMR (CDCl₃) □8.76 (d, 1H), 8.38 (m, 2H), 7.74 (dd, 1H), 7.58 (dd, 1H), 6.79 (d, 1H), 4.38 (dd, 2H), 3.74 (d, 4H), 2.98 (dd, 2H), 2.65 (d, 4H). MS (EI) m/z 303 (M+1).

4-Amino-1-(2-morpholinethoxy)naphthalene hydrochloride: A mixture of 4-nitro-1-(2-morpholinethoxy)naphthalene (40 g, 0.13 mol), MeOH (280 mL) and Pd/C (50% water, 1.2 g) was hydrogenated under 30 psi for 24 h. The catalyst was filtered through a layer of diatomaceous earth under nitrogen. To this filtrate 20 mL of HCl (37%) and cyclohexane (200 mL) were added. The solvent was removed under reduced pressure and the product collected by filtration. The product was dried in vacuum to constant weight. Yield: 33 g, 82%. ¹H NMR (DMSO) □8.38 (d, 1H), 8.00 (d, 1H), 7.72 (dd, 1H), 7.64 (m, 2H), 7.05 (d, 1H), 4.62 (s, 2H), 4.00 (b, 4H), 3.88 (s, 2H), 3.40 (b, 4H). MS (EI) m/z 273 (M⁺).

1-[3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea A solution of 5-(2,2,2-trichloroethoxycarbonyl)amino-3-t-butyl-1-p-tolylpyrazole (10.6 g, 26 mmol), 4-amino-1-(2-morpholinethoxy)naphthalene (free base from HCl salt above, 7.16 g, 26 mmol), diisopropylethylamine (3.2 g, 25 mmol) and DMSO (75 mL) was heated to 55-60° C. and held for 1.5 h. To this solution, ethyl acetate (100 mL) was added. The organic layer was washed with brine (4×50 mL), and dried over MgSO₄. The solvent was removed under reduced pressure, and residue was crystallized from acetonitrile (50 mL) at 0° C. The product was collected by filtration, recrystallized from isopropanol and dried in vacuum to constant weight, m.p.: 151-152° C. Yield: 11.4g, 87%. ¹H NMR (DMSO) □8.75 (s, 1H), 8.51 (s, 1H), 8.21 (d, 1H), 7.85 (d, 1H), 7.65 (d, 1H), 7.55 (m, 2H), 7.49 (dd, 1H), 7.35 (dd, 1H), 6.95 (d, 1H), 6.38 (s, 1H), 4.26 (dd, 2H), 3.60 (dd, 4H), 2.81 (dd, 2H), 2.55 (dd, 4H), 2.38 (s, 3H), 1.29 (s, 9H). MS (CI) m/z 528 (M⁺+1).

EXAMPLE II LPS Study

This study was performed as a randomized, double-blind, placebo-controlled experiment and was performed simultaneously with a study examining the effect of formula (III) on LPS-induced cytokine release and neutrophil activation 14. Briefly, LPS (from E. coli, lot G; United States Pharmacopeial Convention, Rockville, Md.; 4 ng/kg body weight) was administered as a bolus intravenous injection to 24 healthy male volunteers (mean age 22 years, range 19-29). Three hours prior to infusion of LPS, the p38 MAPK inhibitor (III) (600 mg n=8, 50 mg n=8) or placebo (n=8) was administered orally. Blood samples were obtained before administration of (III) or placebo (t=−3 h), directly before LPS administration (t=0 h), and at several time points up to 24 hours thereafter.

Assays

Blood was collected in siliconized vacutainer tubes (Becton Dickinson, Plymouth, England) containing 0.105 M sodium citrate in a 1:9 (v/v) anticoagulant:blood ratio. ELISA's were performed according to the instructions of the manufacturers: prothrombin fragment F1+2 (Dade Behring, Marburg GmbH, Germany), tissue-type plasminogen activator (tPA)(Asserachrom tPA, Diagnostic Stago, Asnieres-sur-Seine, France), plasminogen activator inhibitor type I (PAI-1) (Monozyme, Charlottelund, Denmark), Von Willebrand Factor (vWF) (Dakopatts, Ävlsjö, Sweden), and soluble E-selectin (sE-selectin)(Diaclone, Besancon Cedex, France); plasmin-□2-antiplasmin complexes (PAPc) were determined by a radio immunoassay as described elsewhere¹⁵.

Sepsis—Animal Models

Numerous animal models have been developed in which to simulate the clinical manifestation of septic shock in an attempt to gain further understanding of the disease state and to evaluate possible therapeutic agents. Smaller animal models such as mouse, rats and rabbits afford the investigator the advantages of a screening tool whereby results may be generated faster since larger numbers of animals can be used at one time, however, the disadvantages are that these species have reduced capacity for extensive biochemical analysis (smaller blood volume), show a higher tolerance for bacterial endotoxin (a highly antigenic portion of gram negative bacteria) and are more difficult to instrument when monitoring cardiovascular parameters. Thus, larger animal models are preferred when studying the cardiovascular response to sepsis. Specifically, primate models are described whereby continuous infusion live E. coli or endotoxin is used to simulate the human disease. It has been reported that intravenous administration of E coli or endotoxin can result in systemic hypotension, decreased cardiac output, decreased vascular resistance, pulmonary hypertension, diminished lung compliance, leukopenia and thrombocytopenia. In addition, cardiovascular response, blood flow, leukocyte function and blood coagulation have been studied in primates.

Animal Models—Venous Thrombosis

Numerous models have also been developed to study thrombosis in animals. Rabbit or rat model of venous or arterial thrombosis are know in the literature. Two typical models are: Rabbit deep vein thrombosis model: Briefly, a non-occlusive fibrin-rich thrombus is formed on a thrombogenic surface (cotton threads attached to copper wire) introduced into the abdominal vena cava via the femoral vein of an anesthetized rabbit.

Rabbit/rat/dog arteriovenous shunt model: Briefly, the left femoral artery and vein is isolated, cannulated with polyethylene tubing and connected with a polyethylene shunt containing a 6-cm long cotton thread. The cotton thread is removed 15 min after blood begins to circulate through the shunt, and the thrombus-coated thread is weighed.

All references and patent publications cited in this application are incorporated by reference herein in their entirety.

REFERENCES

1. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J. Med. 1999; 341: 586-592.

2. Van der Poll T, van Deventer S J H. Endotoxemia in healthy subjects as a human model of inflammation. In: Cohen J, Marshall J, ed. The Immune Response in the Critically Ill. Berlin: Springer-Verlag; 1999: 335-357.

3. de Jonge E, Dekkers P E, Creasey A A, Hack C E, Paulson S K, Karim A, Kesecioglu J, Levi M, van Deventer S J, van Der Poll T. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood. 2000; 95: 1124-1129.

4. Creasey A A, Chang A C, Feigen L, Wun T C, Taylor F B, Jr., Hinshaw L B. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest. 1993; 91: 2850-2856.

5. Carr C, Bild G S, Chang A C, Peer G T, Palmier M O, Frazier R B, Gustafson M E, Wun T C, Creasey A A, Hinshaw L B, et al. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock. 1994; 44: 126-137.

6. Levi M, ten Cate H, Bauer K A, van der Poll T, Edgington T S, Buller H R, van Deventer S J, Hack C E, ten Cate J W, Rosenberg R D. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest. 1994; 93: 114-120.

7. Herlaar E, Brown Z. p38 MAPK signalling cascades in inflammatory disease. Mol Med Today. 1999; 5: 439-447.

8. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal. 2000; 12: 1-13.

9. Chu A J, Wang Z G, Walton M A, Seto A. Involvement of MAPK activation in bacterial endotoxin-inducible tissue factor upregulation in human monocytic THP-1 cells. J Surg Res. 2001; 101: 85-90.

10. Blum S, Issbruker K, Willuweit A, Hehlgans S, Lucema M, Mechtcheriakova D, Walsh K, von der Ahe D, Hofer E, Clauss M. An inhibitory role of the phosphatidylinositol 3-kinase-signaling pathway in vascular endothelial growth factor-induced tissue factor expression. J Biol. Chem. 2001; 276: 33428-33434.

11. Eto M, Kozai T, Cosentino F, Joch H, Luscher T F. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation. 2002; 105: 1756-1759.

12. Herkert 0, Diebold I, Brandes R P, Hess J, Busse R, Gorlach A. NADPH oxidase mediates tissue factor-dependent surface procoagulant activity by thrombin in human vascular smooth muscle cells. Circulation. 2002; 105: 2030-2036.

13. Pargellis C, Tong L, Churchill L, Cirillo P F, Gilmore T, Graham A G, Grob P M, Hickey E R, Moss N, Pav S, Regan J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol. 2002; 9: 268-272.

14. Branger J, van Den Blink B, Weijer S, Madwed J, Bos C L, Gupta A, Yong C L, Polmar S H, Olszyna D P, Hack C E, van Deventer S J, Peppelenbosch M P, van der Poll T. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J. Immunol. 2002; 168: 4070-4077.

15. Levi M, de Boer J P, Roem D, ten Cate J W, Hack C E. Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-alpha 2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay. Thromb Haemost. 1992; 67: 111-116.

16. van der Poll T, Levi M, Hack C E, ten Cate H, van Deventer S J, Eerenberg A J, de Groot E R, Jansen J, Gallati H, Buller H R, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med. 1994; 179: 1253-1259.

17. Uchiyama T, Kurabayashi M, Ohyama Y, Utsugi T, Akuzawa N, Sato M, Tomono S, Kawazu S, Nagai R. Hypoxia induces transcription of the plasminogen activator inhibitor-1 gene through genistein-sensitive tyrosine kinase pathways in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2000; 20: 1155-1161.

18. van der Poll T, Coyle S M, Levi M, Jansen P M, Dentener M, Barbosa K, Buurman W A, Hack C E, ten Cate J W, Agosti J M, Lowry S F. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood. 1997; 89: 3727-3734.

19. DeLa Cadena R A, Majluf-Cruz A, Stadnicki A, Tropea M, Reda D, Agosti J M, Colman R W, Suffredini A F. Recombinant tumor necrosis factor receptor p75 fusion protein (TNFR:Fc) alters endotoxin-induced activation of the kinin, fibrinolytic, and coagulation systems in normal humans. Thromb Haemost. 1998; 80: 114-118.

20. Verbon A, Dekkers P E, ten Hove T, Hack C E, Pribble J P, Turner T, Souza S, Axtelle T, Hoek F J, van Deventer S J, van der Poll T. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J. Immunol. 2001; 166: 3599-3605.

21. Marin V, Farnarier C, Gres S, Kaplanski S, Su M S, Dinarello C A, Kaplanski G. The p38 mitogen-activated protein kinase pathway plays a critical role in thrombin-induced endothelial chemokine production and leukocyte recruitment. Blood. 2001; 98: 667-673.

22. Read M A, Whitley M Z, Gupta S, Pierce J W, Best J, Davis R J, Collins T. Tumor necrosis factor alpha-induced E-selectin expression is activated by the nuclear factor-kappaB and c-JUN N-terminal kinase/p38 mitogen-activated protein kinase pathways. J Biol. Chem. 1997; 272: 2753-2761.

23. Jersmann H P, Hii C S, Ferrante J V, Ferrante A. Bacterial lipopolysaccharide and tumor necrosis factor alpha synergistically increase expression of human endothelial adhesion molecules through activation of NF-kappaB and p38 mitogen-activated protein kinase signaling pathways. Infect Immun. 2001; 69: 1273-1279.

24. Fijen J W, Zijlstra J G, De Boer P, Spanjersberg R, Cohen Tervaert J W, Van Der Werf T S, Ligtenberg J J, Tulleken J E. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin Exp Immunol. 2001; 124: 16-20. 

1. A method treating a disease or condition relating to blood coagulation or fibrinolysis comprising administering to a patient in need thereof a pharmaceutically effective a amount of a p38 MAP kinase inhibitor.
 2. The method according to claim 1 wherein the disease or condition is caused by a clot, thrombosis or embolism.
 3. The method according to claim 1 wherein the disease or condition is chosen from: acute venous thrombosis, pulmonary embolism, thrombosis during pregancy, hemorrhagic skin necrosis, acute or chronic disseminated intravascular coagulation (DIC), clot formation from surgery, long bed rest or long periods of immobilization, venous thrombosis, fulminant meningococcemia, acute thrombotic strokes, acute coronary occlusion, acute peripheral arterial occlusion, massive pulmonary embolism, axillary vein thrombosis, massive iliofemoral vein thrombosis, occluded arterial or venous cannulae, cardiomyopathy, venoocclusive disease of the liver, hypotension, decreased cardiac output, decreased vascular resistance, pulmonary hypertension, diminished lung compliance, leukopenia and thrombocytopenia.
 4. The method according to one of claims 1-3 wherein the a p38 MAP kinase inhibitor is provided in combination with one or more other anticoagulant or fibrinolytic agents.
 5. The method according to claim 4 wherein the other anticoagulant or fibrinolytic agents are chosen from recombinant tissue plasminogen activator (rtPA), streptokinase (SK), urokinase (UK), proUK, heparin, enoxoparin, dalteparin, coumarin anticoagulants, aspirin, dipyrimidamole, aggrennox, ticlopidine, clopidogrel (Plavix), abciximab, RheoPro, integrilin, and aggrestat.
 6. The method according to any one of claims 1-5 wherein the a p38 MAP kinase inhibitor is chosen from

or the pharmaceutically acceptable salts thereof. 